<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Tiotropium versus placebo for chronic obstructive pulmonary disease - Karner, C - 2014 | Cochrane Library</title> <meta content="Tiotropium versus placebo for chronic obstructive pulmonary disease - Karner, C - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009285.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Tiotropium versus placebo for chronic obstructive pulmonary disease - Karner, C - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009285.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009285.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Tiotropium versus placebo for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Charlotta Karner" name="citation_author"/> <meta content="BMJ" name="citation_author_institution"/> <meta content="ckarner@bmj.com" name="citation_author_email"/> <meta content="Jimmy Chong" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009285.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/07/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009285.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009285.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009285.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bronchodilator Agents [*therapeutic use]; Cholinergic Antagonists [*therapeutic use]; Disease Progression; Dry Powder Inhalers; Nebulizers and Vaporizers; Placebo Effect; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Scopolamine Derivatives [*therapeutic use]; Tiotropium Bromide" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009285.pub3&amp;doi=10.1002/14651858.CD009285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009285\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009285\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009285.pub3",title:"Tiotropium versus placebo for chronic obstructive pulmonary disease",firstPublishedDate:"Jul 21, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009285.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009285.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009285.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009285.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009285.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009285.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009285.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009285.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009285.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009285.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3631 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009285.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0077"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-sec-0071"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/appendices#CD009285-sec-0082"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/table_n/CD009285StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/table_n/CD009285StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Tiotropium versus placebo for chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information#CD009285-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Charlotta Karner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information#CD009285-cr-0003">Jimmy Chong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information#CD009285-cr-0004">Phillippa Poole</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information/en#CD009285-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 July 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009285.pub3">https://doi.org/10.1002/14651858.CD009285.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009285-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009285-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009285-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009285-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009285-abs-0001" lang="en"> <section id="CD009285-sec-0001"> <h3 class="title" id="CD009285-sec-0001">Background</h3> <p>Tiotropium is an anticholinergic agent which has gained widespread acceptance as a once daily maintenance therapy for symptoms and exacerbations of stable chronic obstructive pulmonary disease (COPD). In the past few years there have been several systematic reviews of the efficacy of tiotropium, however, several new trials have compared tiotropium treatment with placebo, including those of a soft mist inhaler, making an update necessary. </p> </section> <section id="CD009285-sec-0002"> <h3 class="title" id="CD009285-sec-0002">Objectives</h3> <p>To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints. </p> </section> <section id="CD009285-sec-0003"> <h3 class="title" id="CD009285-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group's Specialised Register of Trials (CAGR) and ClinicalTrials.gov up to February 2012. </p> </section> <section id="CD009285-sec-0004"> <h3 class="title" id="CD009285-sec-0004">Selection criteria</h3> <p>We included parallel group RCTs of three months or longer comparing treatment with tiotropium against placebo for patients with COPD. </p> </section> <section id="CD009285-sec-0005"> <h3 class="title" id="CD009285-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion and then extracted data on study quality and the outcome results. We contacted study authors and trial sponsors for additional information, and collected information on adverse effects from all trials. We analysed the data using Cochrane Review Manager 5, RevMan 5.2. </p> </section> <section id="CD009285-sec-0006"> <h3 class="title" id="CD009285-sec-0006">Main results</h3> <p>This review included 22 studies of good methodological quality that had enrolled 23,309 participants with COPD. The studies used similar designs, however, the duration varied from three months to four years. In 19 of the studies, 18 mcg tiotropium once daily via the Handihaler dry powder inhaler was evaluated, and in three studies, 5 or 10 mcg tiotropium once daily via the Respimat soft mist inhaler was evaluated. Compared to placebo, tiotropium treatment significantly improved the mean quality of life (mean difference (MD) ‐2.89; 95% confidence interval (CI) ‐3.35 to ‐2.44), increased the number of participants with a clinically significant improvement (odds ratio (OR) 1.52; 95% CI 1.38 to 1.68), and reduced the number of participants with a clinically significant deterioration (OR 0.65; 95% CI 0.59 to 0.72) in quality of life (measured by the St George's Respiratory Questionnaire (SGRQ)). Tiotropium treatment significantly reduced the number of participants suffering from exacerbations (OR 0.78; 95% CI 0.70 to 0.87). This corresponds to a need to treat 16 patients (95% CI 10 to 36) with tiotropium for a year in order to avoid one additional patient suffering exacerbations, based on the average placebo event rate of 44% from one‐year studies. Tiotropium treatment led to fewer hospitalisations due to exacerbations (OR 0.85; 95% CI 0.72 to 1.00), but there was no statistically significant difference in all‐cause hospitalisations (OR 1.00; 95% CI 0.88 to 1.13) or non‐fatal serious adverse events (OR 1.03; 95% CI 0.97 to 1.10). Additionally, there was no statistically significant difference in all‐cause mortality between the tiotropium and placebo groups (Peto OR 0.98; 95% CI 0.86 to 1.11). However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler (test for subgroup differences: P = 0.01). With the dry powder inhaler there were fewer deaths in the tiotropium group (Peto OR 0.92; 95% CI 0.80 to 1.05) than in the placebo group (yearly rate 2.8%), but with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than in the placebo group (yearly rate 1.8%). It is noted that the rates of patients discontinuing study treatment were uneven, with significantly fewer participants withdrawing from tiotropium treatment than from placebo treatment (OR 0.66; 95% CI 0.59 to 0.73). Participants on tiotropium had improved lung function at the end of the study compared with those on placebo (trough forced expiratory volume in one second (FEV<sub>1)</sub> MD 118.92 mL; 95% CI 113.07 to 124.77). </p> </section> <section id="CD009285-sec-0007"> <h3 class="title" id="CD009285-sec-0007">Authors' conclusions</h3> <p>This review shows that tiotropium treatment was associated with a significant improvement in patients' quality of life and it reduced the risk of exacerbations, with a number needed to treat to benefit (NNTB) of 16 to prevent one exacerbation. Tiotropium also reduced exacerbations leading to hospitalisation but no significant difference was found for hospitalisation of any cause or mortality. Thus, tiotropium appears to be a reasonable choice for the management of patients with stable COPD, as proposed in guidelines. The trials included in this review showed a difference in the risk of mortality when compared with placebo depending on the type of tiotropium delivery device used. However, these results have not been confirmed in a recent trial when 2.5 mcg or 5 mcg of tiotropium via Respimat was used in a direct comparison to the 18 mcg Handihaler. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009285-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009285-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009285-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009285-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009285-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009285-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009285-abs-0002" lang="en"> <h3>Tiotropium for managing COPD</h3> <p>Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions, chronic bronchitis and emphysema. It is caused by smoking or inhaled dust, which leads to blockage or narrowing of the airways. The symptoms include breathlessness and a chronic cough. Tiotropium is an inhaled medication that helps widen the airways (bronchodilator) for up to 24 hours, and is used to manage persistent symptoms of COPD. </p> <p>We found 22 studies including 23,309 participants, comparing the long‐term effectiveness and side effects of tiotropium and placebo. Compared with placebo, tiotropium treatment led to an improvement in quality of life, fewer people had an exacerbation (worsening of COPD symptoms), or exacerbations leading to hospital admissions. The number of people that needed to be treated for a year, for one person to avoid one additional exacerbation was 16 (95% confidence interval (CI) 10 to 36). We found no statistically significant difference between the tiotropium and placebo groups in terms of the number of hospital admissions for any cause, serious adverse events or deaths during the studies. However, when we divided the data depending on whether a dry powder inhaler or a soft mist inhaler was used in the studies, these two subgroups were significantly different. With the dry powder inhaler there were fewer deaths in the tiotropium group than in the placebo group, whereas with the soft mist inhaler there were significantly more deaths in the tiotropium group than in the placebo group. Also, there was a larger number of participants that stopped study medication early in the placebo group than in the tiotropium group. </p> <p>This review shows that treatment with tiotropium improves patients' quality of life, and reduces the risk of exacerbations, including exacerbations leading to hospitalisation. But tiotropium does not reduce hospitalisations for all causes or the number of deaths. Based on the evidence in this review, tiotropium appears to be a reasonable treatment choice for patients with stable COPD. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009285-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009285-sec-0077"></div> <h3 class="title" id="CD009285-sec-0078">Implications for practice</h3> <section id="CD009285-sec-0078"> <p>Compared with placebo, tiotropium treatment was associated with an improvement in COPD patients' quality of life and a reduction in the risk of exacerbations, including exacerbations leading to hospitalisation. Furthermore, tiotropium did not appear to significantly reduce serious adverse events or mortality, but it did lead to an improvement in lung function. </p> <p>This review confirms guideline recommendations for the use of tiotropium in the management of patients with stable COPD, particularly if reduction in exacerbations is the goal. The trials included in the review showed that tiotropium delivered via the Respimat soft mist inhaler was associated with a statistically significant increased risk of mortality. However, it should be emphasised that these were subgroup analyses and not head‐to‐head comparisons. A recent large double‐blind trial of the two delivery devices found no substantial difference in mortality using 2.5 mcg or 5 mcg of tiotropium via Respimat in comparison to 18 mcg via Handihaler. </p> <p>The quality of life data suggest some patients will notice a clear symptomatic benefit with tiotropium treatment and some will not. Given the cost of the medication, it is debatable whether or not to continue treatment indefinitely in those COPD patients who do not have frequent exacerbations, and have no difference in quality of life with tiotropium. </p> </section> <h3 class="title" id="CD009285-sec-0079">Implications for research</h3> <section id="CD009285-sec-0079"> <p>Because of the high and often uneven withdrawal rates in COPD trials, new trials should follow up the vital status of all participants, even if they have withdrawn from the study. </p> <p>Other areas for study include whether the lack of difference seen in serious adverse event rates is an artefact of how events have been counted, or a result of an effect of the medication that outweighs the benefits in terms of reduced exacerbations. The results of this review need to be considered in the light of other Cochrane reviews looking at tiotropium versus LABA and ICS, as well as reviews where it is used as add‐on therapy. This should be considered alongside new and existing evidence on safety concerns for the difference inhaler devices. </p> <p>We suggest there is a need for studies in other ethnic groups and settings, and that cost‐effectiveness data is sought to assist in the clinical decision of whether or not it is prescribed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009285-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009285-sec-0015"></div> <div class="table" id="CD009285-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tiotropium versus placebo for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tiotropium versus placebo for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with COPD who have smoked for ≥ 10 pack‐years<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> tiotropium </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tiotropium </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (SGRQ)</b> </p> <p>Scale 0 to 100, where 100<br/> represents worst possible health status and 0 indicates best possible health status </p> <p>Follow‐up: 3 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐2.89</b> <br/> (‐3.35 to ‐2.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,034<br/> (9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Several studies did not report results for individual treatment groups and reported MD between the groups only. The accepted threshold for a clinically significant difference is ‐4 units </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with a clinically significant improvement (≥ 4 units) in quality of life (SGRQ)</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> <br/> (468 to 517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.52</b> </p> <p>(1.38 to 1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,672<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with a clinically significant worsening (≥ 4 units) in quality of life (SGRQ)</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> <br/> (239 to 277) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b> </p> <p>(0.59 to 0.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,672<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with one or more exacerbations</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>442 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> <br/> (357 to 408) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b> <br/> (0.70 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,309<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with one or more exacerbations requiring hospitalisation</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> <br/> (98 to 131) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.85</b> <br/> (0.72 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,852<br/> (21 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with one or more hospitalisations for any cause</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>234 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>234 per 1000</b> <br/> (212 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b> <br/> (0.88 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,963<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> <br/> (43 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b> <br/> (0.86 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,309<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference; <b>OR:</b> Odds ratio; <b>SGRQ</b>: St George's Respiratory Questionnaire </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Although there was moderate unexplained heterogeneity between the study results (I<sup>2</sup> = 51%), this was deemed not to affect the direction of the effect or have a large effect on the size of the effect. </p> <p><sup>2</sup> The number of participants and/or events were low, leading to wide CIs and imprecision in the result. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009285-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009285-sec-0016"></div> <section id="CD009285-sec-0017"> <h3 class="title" id="CD009285-sec-0017">Description of the condition</h3> <p>Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disease characterised by chronic and progressive breathlessness, cough, sputum production, and airflow obstruction, which leads to restricted activity and poor quality of life (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>). The World Health Organization (WHO) (<a href="./references#CD009285-bbs2-0093" title="World Health Organization. Chronic respiratory diseases. www.who.int. ">WHO</a>) has estimated that COPD is the fourth or fifth most common single cause of death worldwide, and the treatment and management costs present a significant burden to public health. In the UK the annual cost of COPD to the National Health Service (NHS) is estimated to be GBP 1.3 million per 100,000 people (<a href="./references#CD009285-bbs2-0083" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. www.guidance.nice.org.uk/CG101/CostingReport/pdf/English. ">NICE 2011</a>). Furthermore, because of the slow onset and the under‐recognition of the disease, it is heavily under‐diagnosed (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>). COPD comprises a combination of bronchitis and emphysema and involves chronic inflammation and structural changes in the lung. Cigarette smoking is the most important risk factor, however air pollution and occupational dust and chemicals are also recognised risk factors. </p> <p>COPD is a progressive disease leading to reduced lung function over time, even with the best available care. There is currently no cure for COPD, although it is both a preventable and treatable disease. As yet, apart from smoking cessation and non‐pharmacological treatments such as long‐term oxygen therapy in hypoxic patients, no intervention has been shown to reduce mortality (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>). Management of the disease is multi‐facetted and includes interventions for smoking cessation (<a href="./references#CD009285-bbs2-0092" title="Van derMeer ReginaM , WagenaE , OsteloRW , JacobsJE , VanSchayckCP . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD002999] ">Van der Meer 2001</a>), pharmacological treatments (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>), education (<a href="./references#CD009285-bbs2-0071" title="EffingT , MonninkhofEM , Van derValkPD , Van derPalenJ , VanHerwaardenCL , PartridgeMR , et al. Self‐management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2] ">Effing 2007</a>), and pulmonary rehabilitation (<a href="./references#CD009285-bbs2-0080" title="LacasseY , GoldsteinR , Lasserson TobyJ , MartinS . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2] ">Lacasse 2006</a>). Pharmacological therapy is aimed at relieving symptoms; improving exercise tolerance and quality of life; slowing decline and even improving lung function; or preventing or treating exacerbations. COPD exacerbations impair patients' quality of life (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>). Furthermore, a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in use of acute care services or hospitalisations (<a href="./references#CD009285-bbs2-0076" title="HutchinsonA , BrandC , IrvingL , RobertsC , ThompsonP , CampbellD . Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal2010;40(5):364‐71. ">Hutchinson 2010</a>). In the UK, one in eight emergency admissions to hospital is for COPD, which makes it the second largest cause of emergency admissions, and one of the most costly conditions treated by the NHS (<a href="./references#CD009285-bbs2-0083" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. www.guidance.nice.org.uk/CG101/CostingReport/pdf/English. ">NICE 2011</a>). Therefore, pharmacological management aimed at reducing or preventing exacerbations is important. </p> </section> <section id="CD009285-sec-0018"> <h3 class="title" id="CD009285-sec-0018">Description of the intervention</h3> <p>COPD pharmacological management tends to begin with one treatment, with additional therapies introduced as necessary to control symptoms (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>). The first step is often a short‐acting bronchodilator for control of breathlessness when needed: either a short‐acting beta<sub>2</sub>‐agonist (SABA) or the short‐acting anticholinergic ipratropium. For persistent or worsening breathlessness associated with lung function decline, long‐acting bronchodilators may be introduced (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>). Long‐acting bronchodilators include long‐acting beta<sub>2</sub>‐agonists (LABAs), such as salmeterol or formoterol; and the long‐acting anticholinergic agent, tiotropium. Regular treatment with long‐acting bronchodilators may be more efficient and convenient than treatment with regular short‐acting bronchodilators (<a href="./references#CD009285-bbs2-0064" title='BeehKM , BeierJ . The short, the long, and the "ultra‐long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy2010;27(3):150‐59. '>Beeh 2010</a>). For symptomatic patients with severe or very severe COPD (forced expiratory volume in one second (FEV<sub>1)</sub> &lt; 50% predicted), and with repeated exacerbations, <a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment. </p> </section> <section id="CD009285-sec-0019"> <h3 class="title" id="CD009285-sec-0019">How the intervention might work</h3> <p>Tiotropium is an anticholinergic agent, which blocks the action of the neurotransmitter acetylcholine. It has an antagonistic effect on muscarinic acetylcholine receptors. Tiotropium has similar affinity for the five different subtypes of muscarinic receptors (M1‐M5), however airway smooth muscle expresses only the M2 and M3 subtypes (<a href="./references#CD009285-bbs2-0085" title="ProskocilBJ , FryerAD . Beta2‐agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society2005;2(4):305‐10; discussion 311‐2. ">Proskocil 2005</a>). Activation of the M3 receptor stimulates a number of intracellular signalling cascades leading to changes in intracellular Ca<sup>2+</sup> homeostasis and contraction. Tiotropium dissociates slowly from M3 receptors giving a bronchodilator effect lasting over 24 hours, but dissociates rapidly from M2 receptors, which appear to be feedback inhibitory receptors (<a href="./references#CD009285-bbs2-0063" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). </p> <p>Tiotropium has gained widespread acceptance as a once daily maintenance therapy in stable COPD (<a href="./references#CD009285-bbs2-0063" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>; <a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a>) for its effects on symptoms and exacerbations. In a previous Cochrane review (<a href="./references#CD009285-bbs2-0063" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>), tiotropium was shown to reduce the primary endpoint of COPD exacerbations compared to placebo. Within the same review, tiotropium was also associated with a significant benefit over placebo in terms of breathlessness, quality of life, and exacerbations requiring hospitalisation. Similar effects on symptoms and exacerbations were confirmed in a more recent, large RCT of almost 6000 participants followed for over four years (<a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a>). There was, however, no significant effect of tiotropium on lung function decline in this longer study. </p> <p>Currently, tiotropium may be delivered via two different inhalers: the HandiHaler which is a single dose dry powder inhaler; and the Respimat soft mist inhaler which is a novel, propellant‐free, multidose inhaler. Boehringer Ingleheim, the manufacturer of both formulations, has reported a higher all‐cause mortality rate associated with use of the soft mist inhaler, but not with the dry powder inhaler (<a href="./references#CD009285-bbs2-0065" title="BoehringerIngelheim . Tiotropium (SPIRIVA®) RESPIMAT®: Evaluation of fatal events. www.trials.boehringer‐ingelheim.com/res/trial/data/pdf/Pooled_Analysis_U10‐3255‐01.pdf2010. ">Boehringer Ingelheim 2010</a>). Anticholinergic side effects that may occur with tiotropium include dry mouth, constipation and tachycardia (<a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a>), as well as major cardiovascular events (<a href="./references#CD009285-bbs2-0090" title="SinghS . Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD. Evidence Based Medicine2009;14(2):42‐3. ">Singh 2009</a>). </p> <p>Although tiotropium is one of the more expensive drugs on the market, a systematic review suggested that tiotropium monotherapy may be associated with lower hospital and other non‐drug costs; being either cost‐saving or cost‐effective compared with other maintenance monotherapies (<a href="./references#CD009285-bbs2-0081" title="MauskopfJA , BakerCL , MonzBU , JuniperMD . Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. Journal of Medical Economics2010;13(3):403‐17. ">Mauskopf 2010</a>). A cost‐utility analysis has presented conflicting results, suggesting that tiotropium may have an unfavourable cost‐effectiveness ratio linked to the relatively high cost of tiotropium and a relatively low number of hospitalisations in patients who are not on tiotropium treatment (<a href="./references#CD009285-bbs2-0082" title="NeytM , DevrieseS , ThiryN , Van denBruelA . Tiotropium's cost‐effectiveness for the treatment of COPD: a cost‐utility analysis under real‐world conditions. BMC Pulmonary Medicine2010;10:47. ">Neyt 2010</a>). </p> </section> <section id="CD009285-sec-0020"> <h3 class="title" id="CD009285-sec-0020">Why it is important to do this review</h3> <p>The potential clinical risks or benefits of treatment with tiotropium were studied in a previous systematic review (<a href="./references#CD009285-bbs2-0063" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). However, several new trials, including those with a novel soft mist inhaler, have compared tiotropium treatment with placebo, making an update necessary. This will give a clearer picture of the true effects associated with  tiotropium treatment. The review forms part of a suite of reviews on tiotropium treatment: either on its own or in various combinations with LABAs and ICS for the treatment of COPD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009285-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009285-sec-0021"></div> <p>To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with chronic obstructive pulmonary disease (COPD), upon clinically important endpoints. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009285-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009285-sec-0022"></div> <section id="CD009285-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009285-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included RCTs with a parallel group design and of at least 12 weeks duration. We did not include cross‐over trials, as one of the primary outcomes was mortality. </p> </section> <section id="CD009285-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included studies of participants with a diagnosis of COPD, where an external set of criteria was used to screen participants for this condition (e.g. Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society (ATS), British Thoracic Society (BTS), and Thoracic Society of Australia and New Zealand (TSANZ)). </p> </section> <section id="CD009285-sec-0026"> <h4 class="title">Types of interventions</h4> <p>In each study, participants were randomised to receive either inhaled tiotropium bromide or placebo. Tiotropium bromide was allowed in any formulation. Participants were allowed inhaled steroids and other concomitant COPD medication, provided they were not part of the randomised treatment. </p> </section> <section id="CD009285-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD009285-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009285-list-0001"> <li> <p>Quality of life; measured with a scale validated for COPD, such as St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Questionnaire (CRQ). </p> </li> <li> <p>Exacerbations; requiring oral corticosteroids and/or antibiotics.</p> </li> <li> <p>Mortality; all‐cause.</p> </li> <li> <p>Hospital admissions; all‐cause and due to exacerbations.</p> </li> </ol> </p> </section> <section id="CD009285-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009285-list-0002"> <li> <p>Forced expiratory volume in one second (FEV<sub>1</sub>). </p> </li> <li> <p>Non‐fatal serious adverse events; all‐cause and cardiovascular.</p> </li> <li> <p>Withdrawals from study treatment.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009285-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009285-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group's Specialised Register of Trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD009285-sec-0083">Appendix 1</a> for further details). We searched all records in the CAGR coded 'COPD' using the following terms:<br/> <br/> tiotropium OR Spiriva OR HandiHaler OR Respimat<br/> <br/> We also conducted a search of ClinicalTrials.gov in July 2011. The search terms are in <a href="./appendices#CD009285-sec-0089">Appendix 2</a>. We searched all databases from their inception to the present and imposed no restriction on language of publication. </p> </section> <section id="CD009285-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched the manufacturer's website (<a href="./references#CD009285-bbs2-0066" title="Global Clinical Trials Website of Boehringer Ingelheim . http://trials.boehringer‐ingelheim.com/. ">Boehringer Ingleheim Global trials database</a>) for additional study information for studies identified through the electronic searches. </p> </section> </section> <section id="CD009285-sec-0033"> <h3 class="title" id="CD009285-sec-0033">Data collection and analysis</h3> <section id="CD009285-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CK, JC) independently screened the titles and abstracts of citations retrieved through literature searches and obtained those deemed to be potentially relevant. We assigned each reference to a study identifier and assessed them against the inclusion criteria of this protocol. </p> </section> <section id="CD009285-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CK, JC) independently extracted information from each study for the following characteristics. </p> <p> <ol id="CD009285-list-0003"> <li> <p>Design (design, total study duration and run‐in, number of study centres and location, withdrawals, and date of study). </p> </li> <li> <p>Participants (N, mean age, age range, gender, COPD severity, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria). </p> </li> <li> <p>Interventions (run‐in, intervention treatment and inhaler type, control treatment and inhaler type). </p> </li> <li> <p>Outcomes (primary and secondary outcomes specified and collected, and time points reported). </p> </li> </ol> </p> <p>We discussed and resolved any discrepancies in the data, or consulted a third‐party where necessary. </p> </section> <section id="CD009285-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias according to recommendations outlined in The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009285-bbs2-0075" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) for: </p> <p> <ol id="CD009285-list-0004"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear.</p> </section> <section id="CD009285-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009285-sec-0038"> <h5 class="title">Dichotomous data</h5> <p>We analysed dichotomous data variables using Mantel‐Haenzsel odds ratios (ORs) with a fixed‐effect model and 95% confidence intervals (CIs). Where events were rare we employed the Peto OR. Where count data were not available as the number of participants experiencing an event, we analysed it as continuous, time‐to‐event or rate ratios, depending on how it was reported. We transformed reported rate ratios into log rate ratios and analysed them using a fixed‐effect model and Generic Inverse Variance (GIV) in Review Manager 5 (<a href="./references#CD009285-bbs2-0087" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). </p> </section> <section id="CD009285-sec-0039"> <h5 class="title">Continuous data</h5> <p>We analysed continuous outcome data as fixed‐effect mean differences (MDs) with 95% CIs. Where treatment effects were reported as a MD between treatment groups, we entered it using a fixed‐effect model and GIV in Review Manager 5 (<a href="./references#CD009285-bbs2-0087" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). We used end of study as time of analysis for all studies. </p> <p>We used intention‐to‐treat (ITT) analysis on outcomes from all randomised participants, where possible, for primary analyses. </p> <p>We calculated numbers needed to treat for primary outcomes from the pooled OR and its CI, and applied these to appropriate levels of baseline risk. </p> </section> </section> <section id="CD009285-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed dichotomous data using participants as the unit of analysis (rather than events). For continuous data we preferred MD based on change from baseline over MD based on absolute values. </p> </section> <section id="CD009285-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible. </p> </section> <section id="CD009285-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the amount of statistical variation among the study results with the I<sup>2</sup> measurement. </p> </section> <section id="CD009285-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>We minimised reporting bias from non‐publication of studies or selective outcome reporting by using a broad search strategy, contacting study authors directly and checking references of included studies. We visually inspected funnel plots. </p> </section> <section id="CD009285-sec-0044"> <h4 class="title">Data synthesis</h4> <p>We have presented the findings of our primary outcomes in a 'Summary of findings' table using GradePro software. </p> </section> <section id="CD009285-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We subgrouped studies where possible, according to:</p> <p> <ol id="CD009285-list-0005"> <li> <p>severity of disease at baseline (mild (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> I), moderate (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> II), severe (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> III), and very severe (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> IV)); </p> </li> <li> <p>tiotropium formulation (dry powder inhaler, soft mist inhaler);</p> </li> <li> <p>concomitant medication (with or without long‐acting beta<sub>2</sub>‐agonists (LABAs), with or without inhaled corticosteroids (ICS), and with or without both LABAs and ICS); and </p> </li> <li> <p>study duration (&lt; 1 year, ≥ 1 year).</p> </li> </ol> </p> </section> <section id="CD009285-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the sensitivity of our primary outcomes to degree of bias by comparing the overall results with those exclusively from trials assessed as being at low risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009285-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009285-sec-0047"></div> <section id="CD009285-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD009285-sec-0049"> <h4 class="title">Results of the search</h4> <p>The search of the Cochrane Airways Group's Specialised Register of Trials (CAGR) returned 451 references (February 2012), ClinicalTrials.gov generated 119 (July 2011), and we identified four references from other sources. From these, we identified 210 as potentially relevant. After further assessment we found that 153 references belonging to 22 studies were eligible for inclusion (see <a href="./references#CD009285-sec-0108" title="">Characteristics of included studies</a>); we excluded 53 references with reasons given in the <a href="./references#CD009285-sec-0109" title="">Characteristics of excluded studies</a> tables, and five studies are awaiting classification pending retrieval and translation. Searching the manufacturer's website (<a href="./references#CD009285-bbs2-0066" title="Global Clinical Trials Website of Boehringer Ingelheim . http://trials.boehringer‐ingelheim.com/. ">Boehringer Ingleheim Global trials database</a>) we found 22 study reports for 19 of the included studies. For the study flow diagram see <a href="#CD009285-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009285-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009285-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009285-sec-0050"> <h4 class="title">Included studies</h4> <p>For details of each trial see <a href="./references#CD009285-sec-0108" title="">Characteristics of included studies</a>. </p> <section id="CD009285-sec-0051"> <h5 class="title">Study design</h5> <p>All of the included studies were randomised, double‐blind, placebo‐controlled, and of parallel group design. The study duration varied from three months to four years (see <a href="#CD009285-tbl-0002">Table 1</a>). Thirteen studies were performed in a single country and six studies were carried out in study centres in several countries. The majority of study centres were in European or North American countries. One study was performed in China (<a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a>). </p> <div class="table" id="CD009285-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study duration</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0003" title="BeehKM , BeierJ , BuhlR , GerkenFMN . Efficacy of tiotropium (spriva) in patients with COPD switched from previous treatment with short‐acting anticholinergics [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A113 [Poster J27]. BeehKM , BeierJ , BuhlR , Stark‐LorenzenP , GerkenF , MetzdorfN , et al. Efficacy of tiotropium bromide (Spiriva) in patients with chronic‐obstructive pulmonary disease (COPD) of different severities [Wirksamkeit von Tiotropiumbromid (Spiriva)bei verschiedenen Schweregraden derchronisch−obstruktiven Lungenerkrankung (COPD)]. Pneumologie2006;60(6):341‐6. [CTG: NCT00274573] BeehKM , BeierJ , BuhlR , Strak‐LorenzenP , GerkenF , MetzdorfN . Efficacy of tiotropium in patients with mild to moderate COPD [Abstract]. American Thoracic Society 2004 International Conference; 2004 May 21‐26; Florida, USA. 2004:P513. BoehringerIngelheim . Acute and long‐term effects of once daily oral inhalation of tiotropium 18 mcg dry powder inhalation capsules in a placebo controlled parallel group design study in patients with chronic obstructive pulmonary disease (COPD) of different severity. www.trials.boehringer‐ingelheim.com. [trial number: 205.257] ">Beeh 2006</a> </p> <p><a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a> </p> <p><a href="./references#CD009285-bbs2-0010" title="FreemanD . A randomised, double‐blind, parallel group, 12 week study, comparing the effect of once daily tiotropium lactose capsule with placebo in patients with chronic obstructive pulmonary disease (COPD), naive to anticholinergic agents in addition to receiving their usual COPD care. www.trials.boehringer‐ingelheim.com. [trial number: 205.276] FreemanD , LeeA , PriceD . Efficacy and safety of tiotropium in COPD patients in primary care‐the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research2007;8:45. [CTG: NCT00274079] FreemanD , SarnoM , WhiteL , LeeA , PriceD . Spruce: tiotropium in UK primary care [Abstract]. Thorax2004;59(Suppl II):ii100. PriceD , SarnoM , LeeA , FreemanD . SPiRiva usual carE‐ SPRUCE ‐ tiotropium in a UK primary care COPD population other regular inhaled treatment [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:[A43] [Poster: F26]. ">Freeman 2007</a> </p> <p><a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a> </p> <p><a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a> </p> <p><a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a> </p> <p><a href="./references#CD009285-bbs2-0014" title="GarcíaRío , F . A randomised, double‐blind, placebo‐controlled, 12 week trial to evaluate the effect of tiotropium inhalation capsules on the magnitude of exercise, measured using an accelerometer, in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 15 Oct 2007). [CTG: NCT00144326; trial number: 205.269] ">NCT00144326</a> </p> <p><a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a> </p> <p><a href="./references#CD009285-bbs2-0021" title="HuchonG . Effect of a 12‐week treatment with inhaled tiotropium (18 mcg once daily) on lung function and static lung volumes in stable, moderate to severe COPD patients. Correlation to dyspnoea scales: a double‐blind, placebo‐controlled, randomized, parallel group study. www.trials.boehringer‐ingelheim.com. [trial number: 205.215] HuchonG , VerkindreC , BartF , AguilaniuB , GuerinJC , LemerreC , et al. Improvements with tiotropium on endurance measure by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients. European Respiratory Society Congress; 2002 September 14‐18; Stockholm. 2002. VerkindreC , BartF , AguilaniuB , FortinF , GuerinJC , LeMerreC , et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration2006;73(4):420‐7. ">Verkinde 2006</a> </p> <p><a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4188</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0004" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract]. American Thoracic Society 99th International Conference; 2003; May 16 ‐ 21; Seattle. 2003:B024 Poster 420. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. American Thoracic Society Annual Meeting; 2006; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , VanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. DonohueJF , VanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilaton of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. FriedmanM , MoreraG , MenjogeS , KestenS . Reduced COPD exacerbations with tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A270. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:112. HodderR , KestenS , MenjogeS , VielK . Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. International Journal of COPD2007;2(2):157‐67. LangleyJ , Briggs JrD , BhattacharyaS , KestenS , CassinoC . Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long acting beta‐agonist use [Abstract]. European Respiratory Journal2004;24(Suppl 48):289. ">Brusasco 2003</a> </p> <p><a href="./references#CD009285-bbs2-0015" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the proportion of patients experiencing an exacerbation and proportion of patients hospitalized for an exacerbation over 6 months during treatment with tiotropium 18 mcg capsule once daily in patients with COPD in a Veterans Affairs setting. www.trials.boehringer‐ingelheim.com. [trial number: 205.266] NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract] American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. San Diego, 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. San Diego, 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A84. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , Cooper JrJAD , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: A randomized trial. Annals of Internal Medicine2005;143(5):317‐326. [CTG: NCT00274547] RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a> </p> <p><a href="./references#CD009285-bbs2-0020" title="CarronK . A 24 week, randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of 18 mcg of tiotropium inhalation capsules administered by handihaler® once‐daily plus prn albuterol (salbutamol) vs. placebo plusprn albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy. www.trials.boehringer‐ingelheim.com. [trial number: 205.365] SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium Handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus prn salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Thoracic Society 2011 International Conference; 2011 May 13‐18; Denver. 2011; Vol. 183:A1589. TroostersT , WeismanI , DobbelsF , GiardinoN , ValluriSR . Assessing the impact of tiotropium on lung function and physical activity in GOLD Stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. The Open Respiratory Medicine Journal2011;5:1‐9. [CTG: NCT00523991] ">Trooster 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3493</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0019" title="TonnelAB . Effect of a 9‐month treatment of SPIRIVA® on health related quality of life in patients with chronic obstructive pulmonary disease. Validation of a new HRQoL questionnaire appropriate to common daily practice. (TIPHON Study). www.trials.boehringer‐ingelheim.com. [trial number: 205.256] TonnelAB , BravoML , BrunM . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonnelAB , PerezT , GrosboisJM , BravoML , BrunM . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of COPD2008;3(2):301‐10. [CTG: NCT00274053] ">Tonnel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a> </p> <p><a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a> </p> <p><a href="./references#CD009285-bbs2-0005" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology and Therapeutics2005;18(2):75‐81. CasaburiR , BriggsDDJr , DonohueJF , SerbyCW , MenjogeSS , The US Tiotropium Study Group. The spirometric efficacy of once‐daily dosing with tiotropium in stable COPD: a 13‐week multicenter trial. Chest2000;118(5):1294‐302. CasaburiR , MahlerDA , JonesPW , WannerA , San PedroG , ZuwallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5. FriedmanM , MenjogeSS , AntonSF , KestenS . Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics2004;22(11):741‐9. KestenS , FlandersJ , MenjogeSS , SerbyC . Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one‐year placebo‐controlled clinical trials [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:24. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD Conference; 2003; November 14‐15, 2003; Arlington, Virginia. 2003:Abstract no: 1189. KestenS , MenjogeSS , WitekT . The impact of COPD exacerbations (EXAC) on health related quality of life (HRQL) is attenuated by tiotropium [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:23. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (spiriva™), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. San PedroG , EliasDJ , SerbyCW , WitekTJ . Tiotropium (spiriva™): one year bronchodilator efficacy established with once daily dosing in COPD patients. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A749. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SerbyCW , Schwartzstein , Jones , Ries , Killian . Tiotropium: 1‐Yr studies versus placebo/ipratropium. European Respiratory Review2002;12(82):40‐2. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [Abstract]. European Respiratory Society Annual Congress; 2002; September 14‐18; Stockholm. 2002:P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. WitekTJJr , MahlerDA . Meaningful effect size and patterns of response of the transition dyspnea index. Journal of Clinical Epidemiology2003;56(3):248‐55. ZuwallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW . Tiotropium (spiriva™) improves health status in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ZuwallackR , MorganrothJ , LanesS , KestenS . Electrocardiographic evaluations in COPD patients treated with tiotropium in one‐year clinical trials [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:A035 Poster D78. ">Casaburi 2002</a> </p> <p><a href="./references#CD009285-bbs2-0006" title="ChanC . Spiriva assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long‐term treatment in patients with COPD. A one‐year parallel group, double‐blind, randomised, placebo‐controlled study. Boehringer Ingelheim Clinical Trial Register2005. [trial number : 205.259] ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal2007;14(8):465‐72. [CTG: NCT00277264] ">Chan 2007</a> </p> <p><a href="./references#CD009285-bbs2-0009" title="DusserD . Effect of inhaled tiotropium bromide (18 mcg once daily) on the severity of airflow obstruction during long‐term treatment in patients with moderately severe COPD. Impact on severity and incidence of exacerbations. A one‐year parallel‐group, double‐blind, randomized, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.214] DusserD , BravoML , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. [CTG: NCT00274014] DusserD , BravoML , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , BravoML , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , VielK , BravoML , LaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , LanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a> </p> <p><a href="./references#CD009285-bbs2-0016" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society Annual Meeting; 2006 May 19‐24 2006; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco, California, USA. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. [CTG: NCT00405236] PowrieJ , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661. WedzichaJA . A randomised, double‐blind, parallel‐group, placebo‐controlled study to evaluate the changes in inflammatory markers and in induced sputum following treatment with tiotropium inhalation capsules 18 μg once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.270] ">Powrie 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8967</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0007" title='CooperC . A randomized, double‐blind, placebo‐controlled two‐year trial to examine the changes in exercise endurance and COPD patients treated with tiotropium (Spiriva® HandiHaler®) 18 μg once daily (EXACTT trial). www.trials.boehringer‐ingelheim.com. [trial number: 205.368] CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of COPD2010;5:375‐85. [CTG: NCT00525512] CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. "Treadmill endurance during 2 years" treatment with tiotropium in patients with COPD. American Journal of Respiratory and Critical Care Medicine2011;183:A4586. '>Cooper 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5993</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009285-sec-0052"> <h5 class="title">Sample size</h5> <p>The studies included 23,309 participants, of whom 12,697 were randomised to tiotropium treatment and 10,612 to placebo. The size of the studies varied greatly: <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> was the largest study with 5993 participants, and the smallest study only had 60 participants (<a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a>). </p> </section> <section id="CD009285-sec-0053"> <h5 class="title">Participants</h5> <p>The mean age of participants in the different studies was relatively similar, ranging from 60 to 68 years. Most studies had more male than female participants and a similar gender distribution in both treatment groups. In these trials the percentage of men in the studies was roughly 75%, but varied from 60% to 98%. The exception was a few studies with relatively more women, or with more uneven gender distribution between the treatment groups (<a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a>; <a href="./references#CD009285-bbs2-0010" title="FreemanD . A randomised, double‐blind, parallel group, 12 week study, comparing the effect of once daily tiotropium lactose capsule with placebo in patients with chronic obstructive pulmonary disease (COPD), naive to anticholinergic agents in addition to receiving their usual COPD care. www.trials.boehringer‐ingelheim.com. [trial number: 205.276] FreemanD , LeeA , PriceD . Efficacy and safety of tiotropium in COPD patients in primary care‐the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research2007;8:45. [CTG: NCT00274079] FreemanD , SarnoM , WhiteL , LeeA , PriceD . Spruce: tiotropium in UK primary care [Abstract]. Thorax2004;59(Suppl II):ii100. PriceD , SarnoM , LeeA , FreemanD . SPiRiva usual carE‐ SPRUCE ‐ tiotropium in a UK primary care COPD population other regular inhaled treatment [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:[A43] [Poster: F26]. ">Freeman 2007</a>; <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>; <a href="./references#CD009285-bbs2-0016" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society Annual Meeting; 2006 May 19‐24 2006; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco, California, USA. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. [CTG: NCT00405236] PowrieJ , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661. WedzichaJA . A randomised, double‐blind, parallel‐group, placebo‐controlled study to evaluate the changes in inflammatory markers and in induced sputum following treatment with tiotropium inhalation capsules 18 μg once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.270] ">Powrie 2007</a>). Disease severity in the included studies ranged from mild to severe COPD. In a majority of the studies the patients had a mean baseline lung function of less than 50% FEV<sub>1</sub> predicted indicating that a large proportion of participants had severe COPD. Two studies had higher mean FEV<sub>1</sub> % predicted, <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a> at 73% and <a href="./references#CD009285-bbs2-0020" title="CarronK . A 24 week, randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of 18 mcg of tiotropium inhalation capsules administered by handihaler® once‐daily plus prn albuterol (salbutamol) vs. placebo plusprn albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy. www.trials.boehringer‐ingelheim.com. [trial number: 205.365] SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium Handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus prn salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Thoracic Society 2011 International Conference; 2011 May 13‐18; Denver. 2011; Vol. 183:A1589. TroostersT , WeismanI , DobbelsF , GiardinoN , ValluriSR . Assessing the impact of tiotropium on lung function and physical activity in GOLD Stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. The Open Respiratory Medicine Journal2011;5:1‐9. [CTG: NCT00523991] ">Trooster 2011</a> at 66% of predicted. The baseline lung function was generally well balanced between the treatment groups. </p> <p>The included studies had similar inclusion and exclusion criteria. Patients of either sex, with a clinical diagnosis of stable COPD, were eligible for study entry if they were aged over 40 years and had a smoking history of at least 10 pack‐years. Participants were excluded if they had a significant disease other than COPD usually including other significant respiratory conditions such as asthma or a respiratory infection in the weeks before enrolment. The exception was <a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a> in which participants were required to have a diagnosis of asthma as well as COPD. </p> </section> <section id="CD009285-sec-0054"> <h5 class="title">Interventions</h5> <p>All studies used tiotropium and placebo once daily. Three studies used the soft mist inhaler Respimat; <a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a> (5 mcg tiotropium), <a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a> and <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a> (both 5 mcg and 10 mcg tiotropium in each study). All of the other studies used 18 mcg tiotropium via the Handihaler dry powder inhaler as the intervention. </p> </section> <section id="CD009285-sec-0055"> <h5 class="title">Permitted co‐treatment</h5> <p>Most of the included studies allowed participants to continue previously prescribed medication and short‐acting beta<sub>2</sub>‐agonist as needed. In 13 of the included studies it was specified that anticholinergics, other than the study medication, were not allowed during the study (<a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a>; <a href="./references#CD009285-bbs2-0006" title="ChanC . Spiriva assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long‐term treatment in patients with COPD. A one‐year parallel group, double‐blind, randomised, placebo‐controlled study. Boehringer Ingelheim Clinical Trial Register2005. [trial number : 205.259] ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal2007;14(8):465‐72. [CTG: NCT00277264] ">Chan 2007</a>; <a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a>; <a href="./references#CD009285-bbs2-0009" title="DusserD . Effect of inhaled tiotropium bromide (18 mcg once daily) on the severity of airflow obstruction during long‐term treatment in patients with moderately severe COPD. Impact on severity and incidence of exacerbations. A one‐year parallel‐group, double‐blind, randomized, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.214] DusserD , BravoML , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. [CTG: NCT00274014] DusserD , BravoML , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , BravoML , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , VielK , BravoML , LaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , LanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a>; <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>; <a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a>; <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a>; <a href="./references#CD009285-bbs2-0015" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the proportion of patients experiencing an exacerbation and proportion of patients hospitalized for an exacerbation over 6 months during treatment with tiotropium 18 mcg capsule once daily in patients with COPD in a Veterans Affairs setting. www.trials.boehringer‐ingelheim.com. [trial number: 205.266] NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract] American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. San Diego, 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. San Diego, 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A84. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , Cooper JrJAD , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: A randomized trial. Annals of Internal Medicine2005;143(5):317‐326. [CTG: NCT00274547] RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a>; <a href="./references#CD009285-bbs2-0016" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society Annual Meeting; 2006 May 19‐24 2006; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco, California, USA. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. [CTG: NCT00405236] PowrieJ , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661. WedzichaJA . A randomised, double‐blind, parallel‐group, placebo‐controlled study to evaluate the changes in inflammatory markers and in induced sputum following treatment with tiotropium inhalation capsules 18 μg once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.270] ">Powrie 2007</a>; <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a>; <a href="./references#CD009285-bbs2-0019" title="TonnelAB . Effect of a 9‐month treatment of SPIRIVA® on health related quality of life in patients with chronic obstructive pulmonary disease. Validation of a new HRQoL questionnaire appropriate to common daily practice. (TIPHON Study). www.trials.boehringer‐ingelheim.com. [trial number: 205.256] TonnelAB , BravoML , BrunM . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonnelAB , PerezT , GrosboisJM , BravoML , BrunM . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of COPD2008;3(2):301‐10. [CTG: NCT00274053] ">Tonnel 2008</a>; <a href="./references#CD009285-bbs2-0021" title="HuchonG . Effect of a 12‐week treatment with inhaled tiotropium (18 mcg once daily) on lung function and static lung volumes in stable, moderate to severe COPD patients. Correlation to dyspnoea scales: a double‐blind, placebo‐controlled, randomized, parallel group study. www.trials.boehringer‐ingelheim.com. [trial number: 205.215] HuchonG , VerkindreC , BartF , AguilaniuB , GuerinJC , LemerreC , et al. Improvements with tiotropium on endurance measure by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients. European Respiratory Society Congress; 2002 September 14‐18; Stockholm. 2002. VerkindreC , BartF , AguilaniuB , FortinF , GuerinJC , LeMerreC , et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration2006;73(4):420‐7. ">Verkinde 2006</a>; <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a>). Eight studies specified that they did not allow LABAs (<a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a>; <a href="./references#CD009285-bbs2-0006" title="ChanC . Spiriva assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long‐term treatment in patients with COPD. A one‐year parallel group, double‐blind, randomised, placebo‐controlled study. Boehringer Ingelheim Clinical Trial Register2005. [trial number : 205.259] ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal2007;14(8):465‐72. [CTG: NCT00277264] ">Chan 2007</a>; <a href="./references#CD009285-bbs2-0009" title="DusserD . Effect of inhaled tiotropium bromide (18 mcg once daily) on the severity of airflow obstruction during long‐term treatment in patients with moderately severe COPD. Impact on severity and incidence of exacerbations. A one‐year parallel‐group, double‐blind, randomized, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.214] DusserD , BravoML , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. [CTG: NCT00274014] DusserD , BravoML , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , BravoML , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , VielK , BravoML , LaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , LanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a>; <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>; <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a>; <a href="./references#CD009285-bbs2-0019" title="TonnelAB . Effect of a 9‐month treatment of SPIRIVA® on health related quality of life in patients with chronic obstructive pulmonary disease. Validation of a new HRQoL questionnaire appropriate to common daily practice. (TIPHON Study). www.trials.boehringer‐ingelheim.com. [trial number: 205.256] TonnelAB , BravoML , BrunM . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonnelAB , PerezT , GrosboisJM , BravoML , BrunM . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of COPD2008;3(2):301‐10. [CTG: NCT00274053] ">Tonnel 2008</a>; <a href="./references#CD009285-bbs2-0021" title="HuchonG . Effect of a 12‐week treatment with inhaled tiotropium (18 mcg once daily) on lung function and static lung volumes in stable, moderate to severe COPD patients. Correlation to dyspnoea scales: a double‐blind, placebo‐controlled, randomized, parallel group study. www.trials.boehringer‐ingelheim.com. [trial number: 205.215] HuchonG , VerkindreC , BartF , AguilaniuB , GuerinJC , LemerreC , et al. Improvements with tiotropium on endurance measure by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients. European Respiratory Society Congress; 2002 September 14‐18; Stockholm. 2002. VerkindreC , BartF , AguilaniuB , FortinF , GuerinJC , LeMerreC , et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration2006;73(4):420‐7. ">Verkinde 2006</a>; <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a>), three did not allow antileukotrienes (<a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a>; <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a>; <a href="./references#CD009285-bbs2-0019" title="TonnelAB . Effect of a 9‐month treatment of SPIRIVA® on health related quality of life in patients with chronic obstructive pulmonary disease. Validation of a new HRQoL questionnaire appropriate to common daily practice. (TIPHON Study). www.trials.boehringer‐ingelheim.com. [trial number: 205.256] TonnelAB , BravoML , BrunM . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonnelAB , PerezT , GrosboisJM , BravoML , BrunM . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of COPD2008;3(2):301‐10. [CTG: NCT00274053] ">Tonnel 2008</a>), and two did not allow ICS or ICS/LABA combination inhalers (<a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>; <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a>). </p> </section> <section id="CD009285-sec-0056"> <h5 class="title">Outcomes</h5> <p>All of the studies measured lung function using various measures including FEV<sub>1</sub>. Almost all studies reported results on exacerbations. The included studies primarily also looked at health‐related quality of life, dyspnoea, use of rescue medication, general health status and safety. </p> </section> <section id="CD009285-sec-0057"> <h5 class="title">Funding</h5> <p>All studies except <a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a> were sponsored by Boehringer Ingelheim. </p> </section> </section> <section id="CD009285-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded 53 references from 35 studies as they failed to meet the eligibility criteria for the review (see <a href="./references#CD009285-sec-0109" title="">Characteristics of excluded studies</a>): 16 had a study duration shorter than 12 weeks; nine were of cross‐over study design; one was not a RCT; one was a systematic review of data; and five lacked one or both of the treatment groups ‐ tiotropium and placebo. The last three compared tiotropium to placebo, but this was part of a more complex intervention including pulmonary rehabilitation exercise programmes. </p> </section> </section> <section id="CD009285-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>An assessment of the risk of bias is presented in the <a href="./references#CD009285-sec-0108" title="">Characteristics of included studies</a> table, with an overview of the findings in <a href="#CD009285-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD009285-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009285-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009285-sec-0060"> <h4 class="title">Allocation</h4> <p>Boehringer Ingelheim‐sponsored studies (all but <a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a>) used randomisation lists generated using a validated system, which involved a pseudo‐random number generator so that the resulting treatment sequence was both reproducible and non‐predictable. Participants were then allocated study drug treatment either using a third‐party “Interactive Voice Response System” or by assigning the treatment with the lowest number available to the investigator at the time of randomisation. <a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a> did not describe their allocation concealment procedures. </p> </section> <section id="CD009285-sec-0061"> <h4 class="title">Blinding</h4> <p>All of the included studies were of a double‐blind design. In all of the Boehringer Ingelheim studies, Boehringer Ingelheim was responsible for preparing and coding study treatment in a blinded fashion so that study drug and control were indistinguishable. Outcome assessors remained blinded with regard to the treatment assignments up to database lock. In <a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a> the placebo and the study drug had the same appearance. <a href="./references#CD009285-bbs2-0004" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract]. American Thoracic Society 99th International Conference; 2003; May 16 ‐ 21; Seattle. 2003:B024 Poster 420. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. American Thoracic Society Annual Meeting; 2006; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , VanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. DonohueJF , VanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilaton of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. FriedmanM , MoreraG , MenjogeS , KestenS . Reduced COPD exacerbations with tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A270. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:112. HodderR , KestenS , MenjogeS , VielK . Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. International Journal of COPD2007;2(2):157‐67. LangleyJ , Briggs JrD , BhattacharyaS , KestenS , CassinoC . Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long acting beta‐agonist use [Abstract]. European Respiratory Journal2004;24(Suppl 48):289. ">Brusasco 2003</a> and <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a> used a double dummy design. </p> </section> <section id="CD009285-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Several of the studies had relatively low rates of patients withdrawing from the study treatment in both treatment groups. These were assessed as having a low risk of attrition bias (<a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a>; <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>; <a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a>; <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a>; <a href="./references#CD009285-bbs2-0014" title="GarcíaRío , F . A randomised, double‐blind, placebo‐controlled, 12 week trial to evaluate the effect of tiotropium inhalation capsules on the magnitude of exercise, measured using an accelerometer, in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 15 Oct 2007). [CTG: NCT00144326; trial number: 205.269] ">NCT00144326</a>; <a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a>; <a href="./references#CD009285-bbs2-0020" title="CarronK . A 24 week, randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of 18 mcg of tiotropium inhalation capsules administered by handihaler® once‐daily plus prn albuterol (salbutamol) vs. placebo plusprn albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy. www.trials.boehringer‐ingelheim.com. [trial number: 205.365] SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium Handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus prn salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Thoracic Society 2011 International Conference; 2011 May 13‐18; Denver. 2011; Vol. 183:A1589. TroostersT , WeismanI , DobbelsF , GiardinoN , ValluriSR . Assessing the impact of tiotropium on lung function and physical activity in GOLD Stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. The Open Respiratory Medicine Journal2011;5:1‐9. [CTG: NCT00523991] ">Trooster 2011</a>; <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a>). The two longest studies <a href="./references#CD009285-bbs2-0007" title='CooperC . A randomized, double‐blind, placebo‐controlled two‐year trial to examine the changes in exercise endurance and COPD patients treated with tiotropium (Spiriva® HandiHaler®) 18 μg once daily (EXACTT trial). www.trials.boehringer‐ingelheim.com. [trial number: 205.368] CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of COPD2010;5:375‐85. [CTG: NCT00525512] CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. "Treadmill endurance during 2 years" treatment with tiotropium in patients with COPD. American Journal of Respiratory and Critical Care Medicine2011;183:A4586. '>Cooper 2010</a> (two years) and <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> (four years) had high withdrawal rates, especially in the placebo groups which were 39% and 45% respectively. All the other trials had a mix of relatively high and/or uneven withdrawal rates with an unclear risk of bias. However, three of the larger and longer studies followed up the vital status of participants even if they withdrew from the study treatment or prematurely discontinued study participation (<a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a>; <a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a>; <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a>). </p> </section> <section id="CD009285-sec-0063"> <h4 class="title">Selective reporting</h4> <p>All of the studies reported results for outcomes included in this review that had been specified in the methods of published articles or in study reports. </p> </section> </section> <section id="CD009285-sec-0064"> <h3 class="title" id="CD009285-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD009285-tbl-0001"><b>Summary of findings for the main comparison</b> Tiotropium versus placebo for chronic obstructive pulmonary disease</a> </p> <section id="CD009285-sec-0065"> <h4 class="title">Primary outcome: quality of life</h4> <p>Many of the included studies measured health‐related quality of life using either the SGRQ, the CRQ or the Euro Quality of Life ‐ 5 dimensions questionnaire (EQ‐5D). </p> <p>Nine studies involving 13,034 participants used the SGRQ (<a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a>; <a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a>; <a href="./references#CD009285-bbs2-0004" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract]. American Thoracic Society 99th International Conference; 2003; May 16 ‐ 21; Seattle. 2003:B024 Poster 420. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. American Thoracic Society Annual Meeting; 2006; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , VanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. DonohueJF , VanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilaton of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. FriedmanM , MoreraG , MenjogeS , KestenS . Reduced COPD exacerbations with tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A270. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:112. HodderR , KestenS , MenjogeS , VielK . Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. International Journal of COPD2007;2(2):157‐67. LangleyJ , Briggs JrD , BhattacharyaS , KestenS , CassinoC . Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long acting beta‐agonist use [Abstract]. European Respiratory Journal2004;24(Suppl 48):289. ">Brusasco 2003</a>; <a href="./references#CD009285-bbs2-0005" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology and Therapeutics2005;18(2):75‐81. CasaburiR , BriggsDDJr , DonohueJF , SerbyCW , MenjogeSS , The US Tiotropium Study Group. The spirometric efficacy of once‐daily dosing with tiotropium in stable COPD: a 13‐week multicenter trial. Chest2000;118(5):1294‐302. CasaburiR , MahlerDA , JonesPW , WannerA , San PedroG , ZuwallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5. FriedmanM , MenjogeSS , AntonSF , KestenS . Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics2004;22(11):741‐9. KestenS , FlandersJ , MenjogeSS , SerbyC . Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one‐year placebo‐controlled clinical trials [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:24. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD Conference; 2003; November 14‐15, 2003; Arlington, Virginia. 2003:Abstract no: 1189. KestenS , MenjogeSS , WitekT . The impact of COPD exacerbations (EXAC) on health related quality of life (HRQL) is attenuated by tiotropium [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:23. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (spiriva™), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. San PedroG , EliasDJ , SerbyCW , WitekTJ . Tiotropium (spiriva™): one year bronchodilator efficacy established with once daily dosing in COPD patients. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A749. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SerbyCW , Schwartzstein , Jones , Ries , Killian . Tiotropium: 1‐Yr studies versus placebo/ipratropium. European Respiratory Review2002;12(82):40‐2. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [Abstract]. European Respiratory Society Annual Congress; 2002; September 14‐18; Stockholm. 2002:P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. WitekTJJr , MahlerDA . Meaningful effect size and patterns of response of the transition dyspnea index. Journal of Clinical Epidemiology2003;56(3):248‐55. ZuwallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW . Tiotropium (spiriva™) improves health status in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ZuwallackR , MorganrothJ , LanesS , KestenS . Electrocardiographic evaluations in COPD patients treated with tiotropium in one‐year clinical trials [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:A035 Poster D78. ">Casaburi 2002</a>; <a href="./references#CD009285-bbs2-0006" title="ChanC . Spiriva assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long‐term treatment in patients with COPD. A one‐year parallel group, double‐blind, randomised, placebo‐controlled study. Boehringer Ingelheim Clinical Trial Register2005. [trial number : 205.259] ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal2007;14(8):465‐72. [CTG: NCT00277264] ">Chan 2007</a>; <a href="./references#CD009285-bbs2-0007" title='CooperC . A randomized, double‐blind, placebo‐controlled two‐year trial to examine the changes in exercise endurance and COPD patients treated with tiotropium (Spiriva® HandiHaler®) 18 μg once daily (EXACTT trial). www.trials.boehringer‐ingelheim.com. [trial number: 205.368] CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of COPD2010;5:375‐85. [CTG: NCT00525512] CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. "Treadmill endurance during 2 years" treatment with tiotropium in patients with COPD. American Journal of Respiratory and Critical Care Medicine2011;183:A4586. '>Cooper 2010</a>; <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a>; <a href="./references#CD009285-bbs2-0019" title="TonnelAB . Effect of a 9‐month treatment of SPIRIVA® on health related quality of life in patients with chronic obstructive pulmonary disease. Validation of a new HRQoL questionnaire appropriate to common daily practice. (TIPHON Study). www.trials.boehringer‐ingelheim.com. [trial number: 205.256] TonnelAB , BravoML , BrunM . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonnelAB , PerezT , GrosboisJM , BravoML , BrunM . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of COPD2008;3(2):301‐10. [CTG: NCT00274053] ">Tonnel 2008</a>; <a href="./references#CD009285-bbs2-0021" title="HuchonG . Effect of a 12‐week treatment with inhaled tiotropium (18 mcg once daily) on lung function and static lung volumes in stable, moderate to severe COPD patients. Correlation to dyspnoea scales: a double‐blind, placebo‐controlled, randomized, parallel group study. www.trials.boehringer‐ingelheim.com. [trial number: 205.215] HuchonG , VerkindreC , BartF , AguilaniuB , GuerinJC , LemerreC , et al. Improvements with tiotropium on endurance measure by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients. European Respiratory Society Congress; 2002 September 14‐18; Stockholm. 2002. VerkindreC , BartF , AguilaniuB , FortinF , GuerinJC , LeMerreC , et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration2006;73(4):420‐7. ">Verkinde 2006</a>). A decrease in SGRQ score denotes an improvement in quality of life and a difference of at least four units is regarded as clinically significant (<a href="./references#CD009285-bbs2-0089" title="JonesP . St George's Respiratory Questionnaire for COPD Patients (SGRQ‐C). www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ‐C%20Manual%202008.pdf2008. ">SGRQ‐C manual 2008</a>). In <a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a> the 5 mcg and 10 mcg tiotropium groups were similar in size and had similar quality of life data. The two groups were therefore combined using the mean of the groups for both the MD and the standard error (SE). The SE was adjusted by (1/√1.5) to take into account the 50% increase of n. Tiotropium treatment led to a statistically significant improvement in health‐related quality of life compared to placebo (MD ‐2.89; 95% CI ‐3.35 to ‐2.44, <a href="#CD009285-fig-0003">Figure 3</a>). These studies also reported data on the number of participants who had a clinically significant improvement (≥ ‐4 units) or worsening (≥ +4 units) in quality of life. There were significantly more participants with a clinically significant improvement in quality of life (OR 1.52; 95% CI 1.38 to 1.68, <a href="./references#CD009285-fig-0009" title="">Analysis 1.2</a>), and significantly fewer participants with a clinically significant deterioration (OR 0.65; 95% CI 0.59 to 0.72, <a href="./references#CD009285-fig-0010" title="">Analysis 1.3</a>) treated with tiotropium compared to placebo. The heterogeneity between the studies was 26% and 18% for improvement and deterioration, respectively. </p> <div class="figure" id="CD009285-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.1 Quality of life (SGRQ total score)." data-id="CD009285-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.1 Quality of life (SGRQ total score). </p> </div> </div> </div> <p>Subgroup analysis of participants on concomitant medication during the trials showed no statistically significant difference between participants with (518 participants) or without (270 participants) ICS use (test for subgroup differences: P = 0.56, <a href="./references#CD009285-fig-0011" title="">Analysis 1.4</a>), or with (1824 participants) or without (4114 patients) LABA use (test for subgroup differences: P = 0.38, <a href="./references#CD009285-fig-0012" title="">Analysis 1.5</a>). There was no statistically significant difference between participants with a lung function (FEV<sub>1</sub>) of more than 50% predicted (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> I/II, 1945 participants) and participants with FEV<sub>1</sub> predicted of less than 50% (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> III/IV, 290 participants) (test for subgroup differences: P = 0.07, <a href="./references#CD009285-fig-0013" title="">Analysis 1.6</a>). </p> <p>Three studies used the EQ‐5D questionnaire (<a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a>; <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>; <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a>), and one study used the Chronic Respiratory Questionnaire (CRQ) (<a href="./references#CD009285-bbs2-0014" title="GarcíaRío , F . A randomised, double‐blind, placebo‐controlled, 12 week trial to evaluate the effect of tiotropium inhalation capsules on the magnitude of exercise, measured using an accelerometer, in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 15 Oct 2007). [CTG: NCT00144326; trial number: 205.269] ">NCT00144326</a>). EQ‐5D and CRQ are different scales, but in both a higher value signifies better health. <a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a> showed the tiotropium group to have a small but statistically significant improvement in quality of life compared to the placebo group (MD 0.06; 95% CI 0.02 to 0.10; <a href="./references#CD009285-fig-0014" title="">Analysis 1.7</a>). <a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a>, <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a> and <a href="./references#CD009285-bbs2-0014" title="GarcíaRío , F . A randomised, double‐blind, placebo‐controlled, 12 week trial to evaluate the effect of tiotropium inhalation capsules on the magnitude of exercise, measured using an accelerometer, in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 15 Oct 2007). [CTG: NCT00144326; trial number: 205.269] ">NCT00144326</a> showed no statistically significant difference between the groups (<a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a> (MD ‐0.02; 95% CI ‐0.05 to 0.01; <a href="./references#CD009285-fig-0015" title="">Analysis 1.8</a>); <a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a> (P = 0.86, data analysed in a non‐parametric way, mean data therefore not available), <a href="./references#CD009285-bbs2-0014" title="GarcíaRío , F . A randomised, double‐blind, placebo‐controlled, 12 week trial to evaluate the effect of tiotropium inhalation capsules on the magnitude of exercise, measured using an accelerometer, in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 15 Oct 2007). [CTG: NCT00144326; trial number: 205.269] ">NCT00144326</a> (MD ‐2.50; 95% CI ‐56.35 to 51.35)). </p> </section> <section id="CD009285-sec-0066"> <h4 class="title">Primary outcome: exacerbations and hospital admissions</h4> <p>All of the studies reported COPD exacerbations as a specific outcome or as part of the safety data (22 studies, 23,309 participants). The definition of COPD exacerbation was similar among the studies; exacerbations were defined as a complex of respiratory events or symptoms (new onset or an increase in at least one of cough, sputum, dyspnoea or wheeze) that lasted at least three days and required treatment with antibiotics and/or systemic corticosteroids. All of the studies reported the number of participants with one or more exacerbation in each treatment group. There were fewer participants suffering one or more exacerbations in the tiotropium group (38%) than in the placebo group (44%). The difference between the groups was statistically significant when analysed using a fixed‐effect model (OR 0.81; 95% CI 0.76 to 0.86). There was moderate heterogeneity in the result among the studies (I<sup>2</sup> = 51%), although a random‐effects model resulted in a similar, statistically significant result (OR 0.78; 95% CI 0.70 to 0.87, <a href="#CD009285-fig-0004">Figure 4</a>) with a number needed to treat to benefit (NNTB) of 16 (95% CI 10 to 36) over one year (<a href="#CD009285-fig-0005">Figure 5</a>). A funnel plot of the data did not show any obvious asymmetry indicating publication bias (<a href="#CD009285-fig-0006">Figure 6</a>). This was confirmed by <a href="./references#CD009285-bbs2-0072" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997; Vol. 315, issue 7109:629‐34. ">Egger 1997</a> test of asymmetry (P = 0.22). </p> <div class="figure" id="CD009285-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation." data-id="CD009285-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation. </p> </div> </div> </div> <div class="figure" id="CD009285-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="In the placebo group 44 people out of 100 had one or more exacerbations over one year, compared to 38 (95% CI 34 to 41) out of 100 for the tiotropium group." data-id="CD009285-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the placebo group 44 people out of 100 had one or more exacerbations over one year, compared to 38 (95% CI 34 to 41) out of 100 for the tiotropium group. </p> </div> </div> </div> <div class="figure" id="CD009285-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation." data-id="CD009285-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation. </p> </div> </div> </div> <p>When analysing the data according to study length and inhaler device, there was substantial heterogeneity within the subgroups. We therefore analysed the data using a random‐effects model which showed no statistically significant difference between studies of up to one year (7830 patients) and studies longer than one year (15,479 patients) (test for subgroup differences: P = 0.33, <a href="./references#CD009285-fig-0017" title="">Analysis 1.10</a>), or between the different inhalers: dry powder inhaler (16,787 participants) and soft mist inhaler (6522 participants) (test for subgroup differences: P = 0.52, <a href="./references#CD009285-fig-0019" title="">Analysis 1.12</a>). Several studies also reported exacerbation data for the different stages of disease severity (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> II, 3379 participants; <a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> III, 2835 participants; <a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> IV, 533 participants). Because of high heterogeneity within the subgroups, we analysed the data using a random‐effects model. This did not show any statistically significant difference among the groups (test for subgroup differences: P = 0.31, <a href="./references#CD009285-fig-0020" title="">Analysis 1.13</a>). A comparison of patients taking ICS (615 participants) or not (388 participants) showed no statistically significant difference between the groups when analysed using a random‐effects model (test for subgroup differences: P = 0.64, <a href="./references#CD009285-fig-0018" title="">Analysis 1.11</a>). </p> <p>All but one study (<a href="./references#CD009285-bbs2-0020" title="CarronK . A 24 week, randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of 18 mcg of tiotropium inhalation capsules administered by handihaler® once‐daily plus prn albuterol (salbutamol) vs. placebo plusprn albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy. www.trials.boehringer‐ingelheim.com. [trial number: 205.365] SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium Handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus prn salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Thoracic Society 2011 International Conference; 2011 May 13‐18; Denver. 2011; Vol. 183:A1589. TroostersT , WeismanI , DobbelsF , GiardinoN , ValluriSR . Assessing the impact of tiotropium on lung function and physical activity in GOLD Stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. The Open Respiratory Medicine Journal2011;5:1‐9. [CTG: NCT00523991] ">Trooster 2011</a>) reported exacerbations leading to hospitalisation (21 studies, 22,852 participants). There were fewer patients on tiotropium suffering one or more exacerbation(s) leading to hospitalisation (10.4%) than those on placebo (13.1%) (OR 0.85; 95% CI 0.72 to 1.00; <a href="./references#CD009285-fig-0021" title="">Analysis 1.14</a>). There was again moderate heterogeneity in this result (I<sup>2</sup> = 37%). The heterogeneity does not seem to be explained by the use of different inhalers (dry powder inhaler, 16,330 participants; soft mist inhaler, 6522 participants; test for subgroup differences, P = 0.70; <a href="./references#CD009285-fig-0024" title="">Analysis 1.17</a>) or by study duration (&lt; 1 year, 7373 participants; ≥ 1 year, 15,479 participants; test for subgroup differences: P = 1.00; <a href="./references#CD009285-fig-0023" title="">Analysis 1.16</a>). </p> <p>All but three studies reported the number of participants who were hospitalised for any cause (19 studies, 20,963 participants). The exceptions were <a href="./references#CD009285-bbs2-0015" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the proportion of patients experiencing an exacerbation and proportion of patients hospitalized for an exacerbation over 6 months during treatment with tiotropium 18 mcg capsule once daily in patients with COPD in a Veterans Affairs setting. www.trials.boehringer‐ingelheim.com. [trial number: 205.266] NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract] American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. San Diego, 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. San Diego, 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A84. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , Cooper JrJAD , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: A randomized trial. Annals of Internal Medicine2005;143(5):317‐326. [CTG: NCT00274547] RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a>, <a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a>, and <a href="./references#CD009285-bbs2-0020" title="CarronK . A 24 week, randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of 18 mcg of tiotropium inhalation capsules administered by handihaler® once‐daily plus prn albuterol (salbutamol) vs. placebo plusprn albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy. www.trials.boehringer‐ingelheim.com. [trial number: 205.365] SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium Handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus prn salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Thoracic Society 2011 International Conference; 2011 May 13‐18; Denver. 2011; Vol. 183:A1589. TroostersT , WeismanI , DobbelsF , GiardinoN , ValluriSR . Assessing the impact of tiotropium on lung function and physical activity in GOLD Stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. The Open Respiratory Medicine Journal2011;5:1‐9. [CTG: NCT00523991] ">Trooster 2011</a>. There was no statistically significant difference between the tiotropium and the control groups in all‐cause hospitalisations (OR 1.00; 95% CI 0.88 to 1.13; I<sup>2</sup> = 37%; <a href="./references#CD009285-fig-0022" title="">Analysis 1.15</a>). </p> </section> <section id="CD009285-sec-0067"> <h4 class="title">Primary outcome: mortality</h4> <p>All studies reported the number of deaths during the treatment period in each treatment group (22 studies, 23,309 participants). <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> (5993 participants) was the only study to have mortality as a specified outcome, with a mortality adjudication committee evaluating the primary cause of death from blinded data. A couple of other studies also followed up all participants, including those who prematurely discontinued study treatment (<a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a>; <a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a>). In the pooled data there were fewer deaths in the tiotropium group (4.2%) than in the placebo group (4.9%), although the difference was not statistically significant (Peto OR 0.98; 95% CI 0.86 to 1.11; <a href="./references#CD009285-fig-0026" title="">Analysis 1.19</a>). However, there was some heterogeneity among the studies (I<sup>2</sup> = 27%). Subgroup analysis showed no correlation with study duration (&lt; 1 year, 7830 participants; ≥ 1 year, 15,479 participants; test for subgroup differences, P = 0.36; <a href="./references#CD009285-fig-0027" title="">Analysis 1.20</a>), but there was a statistically significant difference between the studies using the dry powder inhaler (16,787 patients) and those using a soft mist inhaler (6522 participants) (test for subgroup differences: P = 0.01; <a href="#CD009285-fig-0007">Figure 7</a>). With the soft mist inhaler there were more deaths in the tiotropium group (2.4%) than the placebo group (1.7%) (Peto OR 1.47; 95% CI 1.04 to 2.08). With the dry powder inhaler there were fewer deaths in the tiotropium group (4.9%) than in the control group (6.1%) (Peto OR 0.92; 95% CI 0.80 to 1.05). The large difference in baseline risk is primarily caused by the large four‐year trial (<a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a>), which drove up the baseline risk in the dry powder inhaler group. </p> <div class="figure" id="CD009285-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.21 Subgroup analysis: mortality by inhaler device." data-id="CD009285-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.21 Subgroup analysis: mortality by inhaler device. </p> </div> </div> </div> <p>Furthermore, <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> reported a breakdown of results according to the concomitant medication taken by participants during the trial. There was no statistically significant difference in mortality among participants taking and those not taking LABAs (test for subgroup differences, P = 0.89; <a href="./references#CD009285-fig-0029" title="">Analysis 1.22</a>), ICS (test for subgroup differences, P = 0.38; <a href="./references#CD009285-fig-0031" title="">Analysis 1.24</a>), or both (test for subgroup differences, P = 1.00; <a href="./references#CD009285-fig-0030" title="">Analysis 1.23</a>). <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> also performed a subgroup analysis based on participants' disease severity. There was no statistically significant difference among those with mild/moderate (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> I/II), severe (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> III), and very severe (<a href="./references#CD009285-bbs2-0074" title="Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.com (accessed 14th December 2009). ">GOLD 2010</a> IV) COPD (test for subgroup differences, P = 0.76; <a href="./references#CD009285-fig-0032" title="">Analysis 1.25</a>). </p> </section> <section id="CD009285-sec-0068"> <h4 class="title">Secondary outcome: Forced expiratory volume in one second (FEV<sub>1</sub>) </h4> <p>All of the included studies looked at lung function in terms of FEV<sub>1</sub>, but this was reported variously as: trough FEV<sub>1</sub>; post‐bronchodilator response at various time points; area under the curve (AUC); or as rate of decline of FEV<sub>1</sub>. Of all the different measures of FEV<sub>1'</sub> all 22 studies reported trough FEV<sub>1</sub>. In <a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a> the 5 mcg and 10 mcg tiotropium groups were similar in size and had similar FEV<sub>1</sub> data. The two intervention groups were therefore combined using the mean of the groups for both the MD and the SE. The SE was adjusted by (1/√1.5) to take into account the 50% increase of n. The pooled analysis (22,764 participants) showed a statistically significant improvement in trough FEV<sub>1</sub> with tiotropium compared to placebo (MD 118.92 mL; 95% CI 113.07 to 124.77; <a href="./references#CD009285-fig-0033" title="">Analysis 1.26</a>). Although there was moderate heterogeneity among the studies (I<sup>2</sup> = 61%), the result was similar when analysed using a random‐effects model (MD 114.76 mL; 95% CI 102.91 to 126.61). </p> </section> <section id="CD009285-sec-0069"> <h4 class="title">Secondary outcome: all‐cause non‐fatal serious adverse events</h4> <p>All included studies (22 studies, 23,309 participants) reported serious adverse events. There was no statistically significant difference in the number of participants suffering one or more serious adverse event between the tiotropium and placebo groups (OR 1.03; 95% CI 0.97 to 1.10; <a href="./references#CD009285-fig-0034" title="">Analysis 1.27</a>). </p> <p>Owing to large differences among studies in whether or not serious adverse cardiovascular events were reported, or the type of events, we have not presented data on this outcome in this version of the review. </p> </section> <section id="CD009285-sec-0070"> <h4 class="title">Secondary outcome: withdrawals from study treatment</h4> <p>All included studies (22 studies, 23,309 participants) reported the number of participants withdrawing from the study treatment before study completion. Even though there was moderate heterogeneity among the studies (I<sup>2</sup>= 44%), there were significantly fewer withdrawals in the tiotropium group compared to the placebo group when analysed using a random‐effects model (OR 0.66; 95% CI 0.59 to 0.73; <a href="./references#CD009285-fig-0035" title="">Analysis 1.28</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009285-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009285-sec-0071"></div> <section id="CD009285-sec-0072"> <h3 class="title" id="CD009285-sec-0072">Summary of main results</h3> <p>This systematic review set out to investigate the long‐term (three months or longer) effects of tiotropium for the treatment of COPD. We identified 22 eligible randomised, parallel group, placebo‐controlled trials with a total of 23,309 participants. All but one of the studies were sponsored by Boehringer Ingelheim (the manufacturer of tiotropium); the studies were generally of high methodological quality although there were moderate to high dropout rates and in some trials these were uneven. In this review we found that compared to placebo, treatment with tiotropium led to a significant mean improvement in quality of life (SGRQ; MD ‐2.89; 95% CI ‐3.35 to ‐2.44), however this mean improvement did not reach the accepted threshold of four units for a clinically significant difference. Yet, there were significantly more patients with a clinically important improvement (OR 1.52; 95% CI 1.38 to 1.68) and fewer patients with a clinically important worsening (OR 0.65; 95% CI 0.59 to 0.72) on tiotropium compared to placebo. Furthermore, tiotropium treatment significantly lowered the risk of exacerbations (OR 0.78; 95% CI 0.70 to 0.87), which would correspond to a total of approximately 16 COPD patients having to be treated with tiotropium for a year to prevent one additional exacerbation. We could not show a difference in the risk of exacerbation related to either disease severity or the type of tiotropium inhaler used. There were fewer patients with severe exacerbations leading to hospitalisation, and deaths among patients on tiotropium than on placebo, but the differences were not statistically significant. We found a statistically significant difference in the number of deaths in participants using the two different types of tiotropium inhaler, but event numbers were low and may have been affected by withdrawal rates which were generally higher than the mortality rates. Patients taking tiotropium using the soft mist inhaler had a significantly increased mortality risk compared to placebo, whereas fewer patients on tiotropium using the dry powder inhaler died then patients on no treatment. Of the secondary outcomes, the trough FEV<sub>1</sub> was significantly improved with tiotropium compared with placebo. A significantly lower number of participants withdrew from the study treatment prematurely in the tiotropium group compared to placebo. There was no statistically significant difference between the number of participants suffering serious adverse events in the intervention and the control groups. </p> </section> <section id="CD009285-sec-0073"> <h3 class="title" id="CD009285-sec-0073">Overall completeness and applicability of evidence</h3> <p>Tiotropium has been on the market for several years. It was approved in Europe in 2002 and in the United States in 2004. To date, numerous trials on tiotropium have been completed. This review includes 22 long‐term studies of high methodological standard, giving robust evidence regarding the relative risks and benefits of tiotropium treatment. </p> <p>When analysing the quality of life data in this review as a MD with a 95% CI, tiotropium treatment led to a statistically significant improvement in health‐related quality of life compared to placebo, although the point estimate and the whole CI were below the threshold of clinical significance (‐4 units). However, analysing the quality of life data as the number of patients with a clinically significant improvement or worsening in quality of life (more than ±4 units) showed a statistically significant difference favouring tiotropium for both outcomes. This shows that even though the mean improvement in SGRQ and the 95% CI were both less than the clinically significant change of 4 units, this is still compatible with significant differences in the proportion of individual patients who experienced a change of four units or more in either direction on their SGRQ. </p> <p>Although a minimal clinically significant difference value for FEV<sub>1</sub> is not well‐established, the MD in trough FEV<sub>1</sub> with tiotropium treatment compared to placebo reached 119 mL in this review, which is within the range of values of 100 to 140 mL that has been suggested (<a href="./references#CD009285-bbs2-0068" title="CazzolaM , MacNeeW , MartinezFJ , RabeKF , FranciosiLG , BarnesPJ , et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal2008; Vol. 31, issue 2:416‐69. ">Cazzola 2008</a>). </p> <p>One of the included studies (<a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a>) enrolled COPD patients with concomitant asthma. They must have had an acute bronchodilator response ≥ 200 mL and ≥ 12% of pre‐bronchodilator FEV<sub>1</sub> either at the screening visit or during the past five years, yet still had a post‐bronchodilator FEV<sub>1</sub> &lt; 80% predicted and a post‐bronchodilator ratio of FEV<sub>1</sub>/forced vital capacity (FVC) &lt; 70%. It is estimated that 10% to 20% of COPD patients have features of asthma (<a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a>). Although this subgroup may represent a substantial part of the COPD population, research regarding the efficacy of different treatments for this group has been limited, as most COPD trials exclude people with any features of asthma. This study did not carry much weight in any of the analyses and its results were similar to other trials. Removing it did not affect the overall results. </p> <p>This review included data from the use of both the dry powder inhaler and soft mist tiotropium inhaler. Although the majority of studies used the dry powder inhaler, almost a third of the participants were enrolled in studies of the soft mist inhaler (6522 patients). The two inhalers were associated with similar improvements in quality of life and reduction of exacerbations, but subgroup comparisons between the results of different trials in the original version of this review highlighted a statistically significant difference in all‐cause mortality between the inhalers. However, as this finding is the result of subgroup analysis it should be interpreted carefully (<a href="./references#CD009285-bbs2-0067" title="CatesCJ . Safety of tiotropium. BMJ2011;342:d2970. ">Cates 2011</a>; <a href="./references#CD009285-bbs2-0084" title="OxmanAD , GuyattGH . A consumer's guide to subgroup analyses. Annals of Internal Medicine1992;116(1):78‐84. ">Oxman 1992</a>). Notwithstanding this reservation, the difference in mortality was noted by the manufacturer of the two inhalers. </p> <p>Recently, a large, industry‐supported prospective randomised, double blind study has found no significant increase in the risk of death or major cardiovascular adverse events with soft mist (Respimat 2.5 mcg or 5 mcg) compared with dry powder (Handihaler 18 mcg) delivery devices for tiotropium (<a href="./references#CD009285-bbs2-0094" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT , DisseB , et al. Tiotropium respimat inhaler and the risk of death in COPD. New England Jounral of Medicine2013;369(16):1491‐501. ">Wise 2013</a>). Over 17,000 participants were followed for a mean period of 2.3 years. The study included patients with a history of cardiac disease and stable heart failure. The trial did not include a placebo group, so we cannot assess whether tiotropium provided a benefit on overall mortality. All three treatment arms had a similar effect on reducing exacerbations. The trial followed up vital status for over 99% of the people who were randomised, but was subject to withdrawal rates of 21‐23% in all arms. Nevertheless the <a href="./references#CD009285-bbs2-0094" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT , DisseB , et al. Tiotropium respimat inhaler and the risk of death in COPD. New England Jounral of Medicine2013;369(16):1491‐501. ">Wise 2013</a> trial provides the least biased evidence currently available, and has allayed some of the concerns of differences in mortality between the delivery devices (at the doses used and in the population studied)<b>.</b> . </p> <p>Information about the efficacy and risks of tiotropium in different ethnic groups is limited. The studies included in this review were conducted in a range of different countries though, when these were specified, they were countries with a predominantly white population. Specific ethnic subgroup analyses have been published for both the <a href="./references#CD009285-bbs2-0015" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the proportion of patients experiencing an exacerbation and proportion of patients hospitalized for an exacerbation over 6 months during treatment with tiotropium 18 mcg capsule once daily in patients with COPD in a Veterans Affairs setting. www.trials.boehringer‐ingelheim.com. [trial number: 205.266] NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract] American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. San Diego, 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. San Diego, 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A84. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , Cooper JrJAD , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: A randomized trial. Annals of Internal Medicine2005;143(5):317‐326. [CTG: NCT00274547] RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a> study, looking at the response to tiotropium in African‐American participants (<a href="./references#CD009285-bbs2-0088" title="RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Rice 2008</a>), and <a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> which examined the subgroup of Asian participants (<a href="./references#CD009285-bbs2-0073" title="FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. ">Fukuchi 2011</a>). Both concluded that tiotropium reduced COPD exacerbations and associated health‐care use to a similar extent in the subgroup as in the whole study population, although the number of participants in the subgroups was low (150 African‐American (<a href="./references#CD009285-bbs2-0088" title="RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Rice 2008</a>), and 362 Asian (<a href="./references#CD009285-bbs2-0073" title="FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. ">Fukuchi 2011</a>) participants). The only study with a non‐white population was one small study undertaken in China (<a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a>, 30 participants). An additional four placebo‐controlled trials of tiotropium, which may be eligible for inclusion in this review, have been undertaken in China (<a href="./references#CD009285-bbs2-0058" title="GuW , SunLH , TanY . Effects of tiotropium on the exercise endurance of patients with COPD. Journal Southeast University (Med. Sci. Edi.)2007;26:332–5. ">Gu 2007</a>; <a href="./references#CD009285-bbs2-0059" title="MinR , HuangM , YinKS , FuWZ , YuWZ . Clinical trial on tiotropium for COPD. Jiangsu Medical Journal2006;32:1078–9. ">Min 2006</a>; <a href="./references#CD009285-bbs2-0061" title="XiaQP , ChenJR , TaoYJ . The curative effect of tiotropium bromide in treating stable COPD. Journal of Clinical Pulmonary Medicine2007;12:1327–8. ">Xia 2007</a>; <a href="./references#CD009285-bbs2-0062" title="YinKS , ZhangDP , ShiY , SunLH , MinR , XiaoYL , et al. A randomized, double‐blind, placebo‐control study of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi2010;33(7):519‐23. ">Yin 2010</a>). However, these were identified too late to be included in this version of the review and so we will assess them in the next update (see <a href="./references#CD009285-sec-0110" title="">Characteristics of studies awaiting classification</a>). </p> <p>Concerns have been expressed about the cardiovascular safety of tiotropium (<a href="./references#CD009285-bbs2-0090" title="SinghS . Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD. Evidence Based Medicine2009;14(2):42‐3. ">Singh 2009</a>). We had planned in the protocol to look at the effect of tiotropium on serious adverse cardiovascular events. However, a more recent systematic review, including 19,545 randomised patients in studies of four weeks or longer, showed that tiotropium was associated with a reduction in the risk of serious cardiovascular events (<a href="./references#CD009285-bbs2-0069" title="CelliB , DecramerM , LeimerI , VogelU , KestenS , TashkinDP . Cardiovascular safety of tiotropium in patients with COPD. Chest2010; Vol. 137, issue 1:20‐30. ">Celli 2010</a>). In this review we did not try to obtain cardiovascular event data for the included studies from the manufacturer, nor additional studies published since <a href="./references#CD009285-bbs2-0069" title="CelliB , DecramerM , LeimerI , VogelU , KestenS , TashkinDP . Cardiovascular safety of tiotropium in patients with COPD. Chest2010; Vol. 137, issue 1:20‐30. ">Celli 2010</a>, so as not to delay publication of this review. </p> </section> <section id="CD009285-sec-0074"> <h3 class="title" id="CD009285-sec-0074">Quality of the evidence</h3> <p>The studies included in this review were of high methodological quality. All but one of the included studies were sponsored by Boehringer Ingelheim, and conducted with similar protocols and definitions. The funnel plot of the exacerbation data, which included all 22 studies, showed no obvious signs of publication bias (<a href="#CD009285-fig-0006">Figure 6</a>). However, for several of the outcomes studied in this review, events are relatively rare, leading to wide CIs and imprecision in the result (<a href="./full#CD009285-tbl-0001">summary of findings Table for the main comparison</a>). Also, as these were long‐term COPD trials, many of them suffered from high and also uneven rates of patients withdrawing from study treatment before the end of the study, or withdrawing from the study altogether. The unknown status of many participants who withdraw from the study, whether they are lost to follow‐up or decline further study, and the large proportion of patients who may have stopped study medication early, has to be taken into account when looking at the evidence. This is especially important for outcomes such as mortality, which have few events compared to withdrawals. In many cases it is the healthier patients or the patients on active treatment that stay in the study, which might lead to a more conservative estimate of the treatment effect (<a href="./references#CD009285-bbs2-0070" title="DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. ">Decramer 2011</a>; <a href="./references#CD009285-bbs2-0078" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. ">Kesten 2007</a>). However, in this review the studies contributing the greater part of the evidence for mortality followed up the vital status of participants who withdrew from the study treatment and from the study. </p> <p>For many of the outcomes there was a certain amount of heterogeneity among the studies. This was addressed with a priori subgroup analyses and random‐effects analyses which take into account heterogeneity in study design. In most cases the causes of the heterogeneity were not able to be identified. </p> </section> <section id="CD009285-sec-0075"> <h3 class="title" id="CD009285-sec-0075">Potential biases in the review process</h3> <p>We performed comprehensive searches to identify relevant studies. We contacted authors of studies with missing data. The manufacturer (Boehringer Ingelheim), which sponsored all but one of the included studies, was accommodating in supplying information about study designs and missing data for several of the studies. </p> </section> <section id="CD009285-sec-0076"> <h3 class="title" id="CD009285-sec-0076">Agreements and disagreements with other studies or reviews</h3> <p>Our results are generally consistent with the findings of others.</p> <p>A systematic review from 2010 looked at RCTs comparing the effect of tiotropium to placebo or active‐control arms on quality of life and dyspnoea (<a href="./references#CD009285-bbs2-0077" title="KaplanA . Effect of tiotropium on quality of life in COPD: a systematic review. Primary Care Respiratory Journal2010;19(4):315‐25. ">Kaplan 2010</a>). This review described the quality of life result from nine trials comparing tiotropium to placebo. Similarly to the present review, <a href="./references#CD009285-bbs2-0077" title="KaplanA . Effect of tiotropium on quality of life in COPD: a systematic review. Primary Care Respiratory Journal2010;19(4):315‐25. ">Kaplan 2010</a> showed a statistically significant improvement with tiotropium in all trials except the two using concurrent pulmonary rehabilitation, which were excluded from our review (<a href="./references#CD009285-bbs2-0023" title="AmbrosinoN , FoglioK , BalzanoG , PaggiaroPL , LessiP , KestenS , et al. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. International Journal of Chronic Obstructive Pulmonary Disease2008;3(4):771‐80. ">Ambrosino 2008</a>; <a href="./references#CD009285-bbs2-0027" title="CasaburiR , KukafkaD , CooperCB , KestenS . Improvement in exercise endurance with the combination of tiotropium and rehabilitative exercise training in COPD patients [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D14. CasaburiR , KukafkaD , CooperCB , WitekTJJr , KestenS . Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest2005;127(3):809‐17. CooperCB , KukafkaD , CasburiR , KestenS . Tiotropium augments improvements in dyspnea and health‐related quality of life following pulmonary rehabilitation in COPD patients [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C22 Poster 507. KestenS , CasaburiR , KukafkaD , CooperCB . Improvement in self‐reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. International Journal of COPD2008;3(1):127‐36. ">Casaburi 2005</a>). <a href="./references#CD009285-bbs2-0095" title="YohannesAM , WillgossTG , VestboJ . Tiotropium for treatment of stable COPD: a meta‐analysis of clinically relevant outcomes. Respiratory Care2011;56(4):477‐87. ">Yohannes 2011</a> is another systematic review which looked at the effectiveness of tiotropium versus placebo, ipratropium or LABA. The review had similar selection criteria to our review, but at the time only identified 11 studies comparing tiotropium with placebo. The review reported comparable results for patients with a clinically significant improvement in quality of life (six studies, OR 1.61; 95% CI 1.38 to 1.88) comparable to this review (nine studies, OR 1.54; 95% CI 1.40 to 1.70). They also examined the proportion of patients with a clinically significant change in the Transition Dyspnoea Index (TDI) which was in favour of tiotropium (two studies, OR 1.96; 95% CI 1.58 to 2.44). Similarly to our review, <a href="./references#CD009285-bbs2-0095" title="YohannesAM , WillgossTG , VestboJ . Tiotropium for treatment of stable COPD: a meta‐analysis of clinically relevant outcomes. Respiratory Care2011;56(4):477‐87. ">Yohannes 2011</a> showed a significant reduction in the OR of patients having exacerbations (11 studies, OR 0.83; 95% CI 0.72 to 0.94) and exacerbation‐related hospitalisations (seven studies, OR 0.89; 95% CI 0.80 to 0.98). They also showed no statistically significant difference in the number of patients experiencing a serious adverse event (OR 1.06; 95% CI 0.97 to 1.17). </p> <p><a href="./references#CD009285-bbs2-0069" title="CelliB , DecramerM , LeimerI , VogelU , KestenS , TashkinDP . Cardiovascular safety of tiotropium in patients with COPD. Chest2010; Vol. 137, issue 1:20‐30. ">Celli 2010</a> is a safety review of Boehringer Ingelheim‐sponsored tiotropium trials (19,545 patients). It included data from 18 of the studies included in our review, plus an additional eight trials, which did not fit the inclusion criteria for this review. The pooled result showed a significant decrease in both fatal (RR 0.88; 95% CI 0.77 to 1.00) and serious adverse events (RR 0.94; 95% CI 0.89 to 1.00, including fatal events) with tiotropium. Meta‐analysis of cardiovascular data from these trials showed tiotropium to be associated with a reduction in major cardiovascular events (RR 0.83; 95% CI 0.71 to 0.98) and fatal cardiovascular events (RR 0.77; 95% CI 0.60 to 0.98). The cardiovascular composite endpoint included fatal events in the system organ classes cardiac and vascular disorders combined with myocardial infarction (fatal and non‐fatal), stroke (fatal and non‐fatal), and the preferred terms sudden death, sudden cardiac death, and cardiac death. </p> <p><a href="./references#CD009285-bbs2-0079" title="KestenS , CelliB , DecramerM , LeimerI , TashkinD . Tiotropium HandiHaler in the treatment of COPD: a safety review. International Journal of Chronic Obstructive Pulmonary Disease2009;4:397‐409. ">Kesten 2009</a> is another safety review of Boehringer Ingelheim‐sponsored tiotropium trials but only covering trials using the dry powder inhaler. It included 24 trials with a minimum of four weeks duration. Of these 17 were included in our review. Presenting the data as a risk difference per 100 patient‐years at risk showed a significantly lowered risk for mortality with tiotropium compared to placebo (RD ‐0.63; 95% CI ‐1.14 to ‐0.12) (<a href="./references#CD009285-bbs2-0079" title="KestenS , CelliB , DecramerM , LeimerI , TashkinD . Tiotropium HandiHaler in the treatment of COPD: a safety review. International Journal of Chronic Obstructive Pulmonary Disease2009;4:397‐409. ">Kesten 2009</a>). The lower number of deaths in the tiotropium group compared to placebo corresponds well with the results for mortality in the dry powder inhaler group in our review. <a href="./references#CD009285-bbs2-0079" title="KestenS , CelliB , DecramerM , LeimerI , TashkinD . Tiotropium HandiHaler in the treatment of COPD: a safety review. International Journal of Chronic Obstructive Pulmonary Disease2009;4:397‐409. ">Kesten 2009</a> found a statistically significant decrease in serious adverse events (RD ‐1.41; 95% CI ‐2.81 to ‐0.00) using tiotropium dry powder inhaler. Our meta‐analysis of this outcome did not show a statistically significant difference in the numbers of patients with non‐fatal serious adverse events between tiotropium and placebo, whether looking at all studies or just studies using the dry powder inhaler. The discrepancy in the results may be due to <a href="./references#CD009285-bbs2-0079" title="KestenS , CelliB , DecramerM , LeimerI , TashkinD . Tiotropium HandiHaler in the treatment of COPD: a safety review. International Journal of Chronic Obstructive Pulmonary Disease2009;4:397‐409. ">Kesten 2009</a> including fatal serious adverse events in their data. </p> <p><a href="./references#CD009285-bbs2-0091" title="SinghS , LokeYK , EnrightPL , FurbergCD . Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta‐analysis of randomised controlled trials. BMJ2011;342:d3215. ">Singh 2011</a> presented mortality data from a systematic search of soft mist inhaler trials. The review included the same trials as this review, showing an increased risk of mortality with the soft mist inhaler. Another systematic review has looked at direct comparisons between the soft mist inhaler and other inhaler devices (<a href="./references#CD009285-bbs2-0086" title="RamFS , CarvallhoCR , WhiteJ . Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. International Journal of Chronic Obstructive Pulmonary Disease2011; Vol. 6:129‐39. ">Ram 2011</a>). It found three studies looking at the difference between tiotropium via soft mist inhaler and tiotropium via dry powder inhaler. These were short‐term (three to four weeks) cross‐over or parallel group trials, hence not eligible for our review. Similarly to our trial, they showed no statistically significant difference between soft mist and dry powder inhaler in the risk of exacerbation (715 patients, RR 0.94; 95% CI 0.58 to 1.54). The results of a large head‐to‐head study comparing the dry powder and the soft mist inhaler for tiotropium have now been reported (<a href="./references#CD009285-bbs2-0094" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT , DisseB , et al. Tiotropium respimat inhaler and the risk of death in COPD. New England Jounral of Medicine2013;369(16):1491‐501. ">Wise 2013</a>) and have not confirmed any important difference in mortality between the soft mist and dry powder inhalers. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009285-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009285-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009285-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.1 Quality of life (SGRQ total score)." data-id="CD009285-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.1 Quality of life (SGRQ total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation." data-id="CD009285-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="In the placebo group 44 people out of 100 had one or more exacerbations over one year, compared to 38 (95% CI 34 to 41) out of 100 for the tiotropium group." data-id="CD009285-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>In the placebo group 44 people out of 100 had one or more exacerbations over one year, compared to 38 (95% CI 34 to 41) out of 100 for the tiotropium group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation." data-id="CD009285-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Tiotropium versus placebo, outcome: 1.9 Patients with ≥ 1 exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.21 Subgroup analysis: mortality by inhaler device." data-id="CD009285-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium versus placebo, outcome: 1.21 Subgroup analysis: mortality by inhaler device. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 1 Quality of life (SGRQ total score)." data-id="CD009285-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 1 Quality of life (SGRQ total score).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 2 Patients with ≥ 4 units improvement in quality of life (SGRQ)." data-id="CD009285-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 2 Patients with ≥ 4 units improvement in quality of life (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 3 Patients with ≥ 4 units worsening in quality of life (SGRQ)." data-id="CD009285-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 3 Patients with ≥ 4 units worsening in quality of life (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 4 Subgroup analysis: Quality of life ICS/ no ICS (SGRQ)." data-id="CD009285-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 4 Subgroup analysis: Quality of life ICS/ no ICS (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 5 Subgroup analysis: Quality of life LABA/ no LABA (SGRQ)." data-id="CD009285-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 5 Subgroup analysis: Quality of life LABA/ no LABA (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 6 Subgroup analysis: Quality of life (SGRQ) by disease severity." data-id="CD009285-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 6 Subgroup analysis: Quality of life (SGRQ) by disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 7 Quality of life (EQ‐5D total score)." data-id="CD009285-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 7 Quality of life (EQ‐5D total score).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 8 Quality of life (CRQ total score)." data-id="CD009285-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 8 Quality of life (CRQ total score).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 9 Patients with ≥ 1 exacerbation." data-id="CD009285-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 9 Patients with ≥ 1 exacerbation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 10 Subgroup analysis: patients with ≥ 1 exacerbation by study duration." data-id="CD009285-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 10 Subgroup analysis: patients with ≥ 1 exacerbation by study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 11 Subgroup analysis: patients with ≥ 1 exacerbations ICS/ no ICS by concomitant medication." data-id="CD009285-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 11 Subgroup analysis: patients with ≥ 1 exacerbations ICS/ no ICS by concomitant medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 12 Subgroup analysis: patients with ≥ 1 exacerbation by inhaler device." data-id="CD009285-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 12 Subgroup analysis: patients with ≥ 1 exacerbation by inhaler device. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 13 Subgroup analysis: patients with ≥ 1 exacerbation by disease severity." data-id="CD009285-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 13 Subgroup analysis: patients with ≥ 1 exacerbation by disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 14 Patients with ≥ 1 exacerbation requiring hospitalisation." data-id="CD009285-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 14 Patients with ≥ 1 exacerbation requiring hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 15 Patients with ≥ 1 hospitalisation (all‐cause)." data-id="CD009285-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 15 Patients with ≥ 1 hospitalisation (all‐cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 16 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by study duration." data-id="CD009285-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 16 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 17 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by inhaler device." data-id="CD009285-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 17 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by inhaler device. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 18 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by disease severity." data-id="CD009285-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 18 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 19 Mortality." data-id="CD009285-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 19 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 20 Subgroup analysis: mortality by study duration." data-id="CD009285-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 20 Subgroup analysis: mortality by study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-21.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 21 Subgroup analysis: mortality by inhaler device." data-id="CD009285-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 21 Subgroup analysis: mortality by inhaler device. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 22 Subgroup analysis: mortality LABA/ no LABAby concomitant medication." data-id="CD009285-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 22 Subgroup analysis: mortality LABA/ no LABAby concomitant medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 23 Subgroup analysis: mortality ICS/LABA/ no ICS/LABA by concomitant medication." data-id="CD009285-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 23 Subgroup analysis: mortality ICS/LABA/ no ICS/LABA by concomitant medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 24 Subgroup analysis: mortality ICS/ no ICS by concomitant medication." data-id="CD009285-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 24 Subgroup analysis: mortality ICS/ no ICS by concomitant medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 25 Subgroup analysis: mortality by disease severity." data-id="CD009285-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 25 Subgroup analysis: mortality by disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 26 Trough FEV1." data-id="CD009285-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 26 Trough FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 27 Patients with ≥ 1 serious adverse event (non‐fatal)." data-id="CD009285-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 27 Patients with ≥ 1 serious adverse event (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 28 Withdrawals." data-id="CD009285-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 28 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 29 Sensitivity analysis of SGRQ responders imputing 0% for missing participants." data-id="CD009285-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 29 Sensitivity analysis of SGRQ responders imputing 0% for missing participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009285-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/urn:x-wiley:14651858:media:CD009285:CD009285-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_t/tCD009285-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium versus placebo, Outcome 30 Sensitivity analysis of SGRQ responders imputing 20% for missing participants." data-id="CD009285-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium versus placebo, Outcome 30 Sensitivity analysis of SGRQ responders imputing 20% for missing participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/media/CDSR/CD009285/image_n/nCD009285-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009285-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tiotropium versus placebo for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tiotropium versus placebo for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with COPD who have smoked for ≥ 10 pack‐years<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> tiotropium </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tiotropium </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (SGRQ)</b> </p> <p>Scale 0 to 100, where 100<br/> represents worst possible health status and 0 indicates best possible health status </p> <p>Follow‐up: 3 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐2.89</b> <br/> (‐3.35 to ‐2.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,034<br/> (9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Several studies did not report results for individual treatment groups and reported MD between the groups only. The accepted threshold for a clinically significant difference is ‐4 units </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with a clinically significant improvement (≥ 4 units) in quality of life (SGRQ)</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> <br/> (468 to 517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.52</b> </p> <p>(1.38 to 1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,672<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with a clinically significant worsening (≥ 4 units) in quality of life (SGRQ)</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> <br/> (239 to 277) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b> </p> <p>(0.59 to 0.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,672<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with one or more exacerbations</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>442 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> <br/> (357 to 408) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b> <br/> (0.70 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,309<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with one or more exacerbations requiring hospitalisation</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> <br/> (98 to 131) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.85</b> <br/> (0.72 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22,852<br/> (21 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with one or more hospitalisations for any cause</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>234 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>234 per 1000</b> <br/> (212 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.00</b> <br/> (0.88 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,963<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 3 to 48 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> <br/> (43 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b> <br/> (0.86 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,309<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference; <b>OR:</b> Odds ratio; <b>SGRQ</b>: St George's Respiratory Questionnaire </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Although there was moderate unexplained heterogeneity between the study results (I<sup>2</sup> = 51%), this was deemed not to affect the direction of the effect or have a large effect on the size of the effect. </p> <p><sup>2</sup> The number of participants and/or events were low, leading to wide CIs and imprecision in the result. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tiotropium versus placebo for chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009285-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study duration</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0003" title="BeehKM , BeierJ , BuhlR , GerkenFMN . Efficacy of tiotropium (spriva) in patients with COPD switched from previous treatment with short‐acting anticholinergics [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A113 [Poster J27]. BeehKM , BeierJ , BuhlR , Stark‐LorenzenP , GerkenF , MetzdorfN , et al. Efficacy of tiotropium bromide (Spiriva) in patients with chronic‐obstructive pulmonary disease (COPD) of different severities [Wirksamkeit von Tiotropiumbromid (Spiriva)bei verschiedenen Schweregraden derchronisch−obstruktiven Lungenerkrankung (COPD)]. Pneumologie2006;60(6):341‐6. [CTG: NCT00274573] BeehKM , BeierJ , BuhlR , Strak‐LorenzenP , GerkenF , MetzdorfN . Efficacy of tiotropium in patients with mild to moderate COPD [Abstract]. American Thoracic Society 2004 International Conference; 2004 May 21‐26; Florida, USA. 2004:P513. BoehringerIngelheim . Acute and long‐term effects of once daily oral inhalation of tiotropium 18 mcg dry powder inhalation capsules in a placebo controlled parallel group design study in patients with chronic obstructive pulmonary disease (COPD) of different severity. www.trials.boehringer‐ingelheim.com. [trial number: 205.257] ">Beeh 2006</a> </p> <p><a href="./references#CD009285-bbs2-0008" title="BoehringerIngelheim . Efficacy and safety (including 24‐hour holter monitoring) of tiotropium inhalation capsules in patients with chronic obstructive pulmonary disease (a 12‐week, parallel group, randomized, placebo‐controlled, double‐blind study). www.trials.boehringer‐ingelheim.com. [trial number: 205.284] CovelliH , BhattacharyaS , CassinoC , ConoscentiC , KestenS . Absence of electrocardiographic findings and improved function with once‐daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy2005; Vol. 25, issue 12:1708‐18. [CTG: NCT00239460] KestenS , CassinoC , ConoscentiC . Absence of electrocardiographic findings with daily tiotropium in patients with chronic obstructive pulmonary disease [Abstract]. Chest2004;126(4 Suppl):837S. ">Covelli 2005</a> </p> <p><a href="./references#CD009285-bbs2-0010" title="FreemanD . A randomised, double‐blind, parallel group, 12 week study, comparing the effect of once daily tiotropium lactose capsule with placebo in patients with chronic obstructive pulmonary disease (COPD), naive to anticholinergic agents in addition to receiving their usual COPD care. www.trials.boehringer‐ingelheim.com. [trial number: 205.276] FreemanD , LeeA , PriceD . Efficacy and safety of tiotropium in COPD patients in primary care‐the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research2007;8:45. [CTG: NCT00274079] FreemanD , SarnoM , WhiteL , LeeA , PriceD . Spruce: tiotropium in UK primary care [Abstract]. Thorax2004;59(Suppl II):ii100. PriceD , SarnoM , LeeA , FreemanD . SPiRiva usual carE‐ SPRUCE ‐ tiotropium in a UK primary care COPD population other regular inhaled treatment [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:[A43] [Poster: F26]. ">Freeman 2007</a> </p> <p><a href="./references#CD009285-bbs2-0011" title="JohanssonG . A 12‐week, double‐blind, randomised, parallel‐group, multi‐centre study evaluating the efficacy of tiotropium versus placebo in patients with mild COPD according to Swedish guidelines (SPIRIMILD). www.trials.boehringer‐ingelheim.com. [trial number: 205.281] JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):616s [E3614]. JohanssonG , LindbergA , RombergK , NordstromL , GerkenF , RoquetA . Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Primary Care Respiratory Journal2008; Vol. 17, issue 3:169‐75. [CTG: NCT00144196] ">Johansson 2008</a> </p> <p><a href="./references#CD009285-bbs2-0012" title="BoehringerIngelheim . A trial evaluating the efficacy and safety of inhaled tiotropium 18 µg qd in patients with COPD and a concomitant diagnosis of asthma. www.clinicaltrials.gov2005. MagnussenH . A 12‐week randomised, double blind, placebo‐controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18 μg q.d. in patients with COPD and a concomitant diagnosis of asthma. www.trials.boehringer‐ingelheim.com. [trial number: 205.301] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS . Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine2008;102(1):50‐6. [CTG: NCT00152984] MagnussenH , BugnasB , VanNoordJ , SchmidtP , GerkenF , KestenS , et al. Spirometric improvements with tiotropium in COPD patients with concomitant asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A5. ">Magnussen 2008</a> </p> <p><a href="./references#CD009285-bbs2-0013" title="BoehringerIngelheim . Spiriva® assessment of FEV1 ‐ (SAFE‐Portugal). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during treatment in patients with COPD. A three‐month parallel group, double‐blind, randomised, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.282] MoitaJ , BarbaraC , CardosoJ , CostaR , SousaM , RuizJ , et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology and Therapeutics2008;21(1):146‐51. [CTG: NCT00239408] MoitaJ , CostaR , BarbaraC , CardosaJ , RulzJ , SousaM . The effect of tiotropium bromide in a stable cohort of COPD patients in Portugal [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1955. ">Moita 2008</a> </p> <p><a href="./references#CD009285-bbs2-0014" title="GarcíaRío , F . A randomised, double‐blind, placebo‐controlled, 12 week trial to evaluate the effect of tiotropium inhalation capsules on the magnitude of exercise, measured using an accelerometer, in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 15 Oct 2007). [CTG: NCT00144326; trial number: 205.269] ">NCT00144326</a> </p> <p><a href="./references#CD009285-bbs2-0017" title="SunLH , TanY , QiaoY , FangSR , XieH . Evaluation of clinical effect and safety of tiotropium bromide in treating stable chronic obstructive pulmonary disease. Zhongguo Xinyao yu Linchuang Zazhi2007;26(5):328‐31. YanL , LuYK . Effect of domestic tiotropium bromide inhalation in patients with COPD at stable stage. Chinese Journal of New Drugs2010;19(2):127‐129, 138. ">Sun 2007</a> </p> <p><a href="./references#CD009285-bbs2-0021" title="HuchonG . Effect of a 12‐week treatment with inhaled tiotropium (18 mcg once daily) on lung function and static lung volumes in stable, moderate to severe COPD patients. Correlation to dyspnoea scales: a double‐blind, placebo‐controlled, randomized, parallel group study. www.trials.boehringer‐ingelheim.com. [trial number: 205.215] HuchonG , VerkindreC , BartF , AguilaniuB , GuerinJC , LemerreC , et al. Improvements with tiotropium on endurance measure by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients. European Respiratory Society Congress; 2002 September 14‐18; Stockholm. 2002. VerkindreC , BartF , AguilaniuB , FortinF , GuerinJC , LeMerreC , et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration2006;73(4):420‐7. ">Verkinde 2006</a> </p> <p><a href="./references#CD009285-bbs2-0022" title="BoehringerIngelheim . A randomised, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses [5 mcg (2 actuations of 2.5 mcg) and 10 mcg (2 actuations of 5 mcg)] of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.251] BoehringerIngelheim . A randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, parallel group efficacy and safety comparison of 12‐week treatment of two doses (5 Mcg and 10 Mcg) of tiotropium inhalation solution delivered by the Respimat inhaler, placebo and ipratropium bromide inhalation aerosol (MDI) in patients with chronic obstructive pulmonary disease (COPD). www.clinicaltrials.gov2002; Vol. Sept 2004 End Date. [trial number: 205.252] VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomised study of tiotropium Respimat soft mist inhaler versus ipratropium PMDI in chronic obstructive pulmonary disease [Abstract]. Thorax2006;61(Suppl 2):ii40 [S112]. VoshaarT , LapidusR , Maleki‐YazdiR , TimmerW , RubinE , LoweL , et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine2008;102(1):32‐41. [CTG: NCT00239473; CTG: NCT00240435] ">Voshaar 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4188</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0004" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract]. American Thoracic Society 99th International Conference; 2003; May 16 ‐ 21; Seattle. 2003:B024 Poster 420. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. American Thoracic Society Annual Meeting; 2006; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , VanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. DonohueJF , VanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilaton of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26. FriedmanM , MoreraG , MenjogeS , KestenS . Reduced COPD exacerbations with tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A270. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:112. HodderR , KestenS , MenjogeS , VielK . Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. International Journal of COPD2007;2(2):157‐67. LangleyJ , Briggs JrD , BhattacharyaS , KestenS , CassinoC . Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long acting beta‐agonist use [Abstract]. European Respiratory Journal2004;24(Suppl 48):289. ">Brusasco 2003</a> </p> <p><a href="./references#CD009285-bbs2-0015" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the proportion of patients experiencing an exacerbation and proportion of patients hospitalized for an exacerbation over 6 months during treatment with tiotropium 18 mcg capsule once daily in patients with COPD in a Veterans Affairs setting. www.trials.boehringer‐ingelheim.com. [trial number: 205.266] NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract] American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. San Diego, 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. San Diego, 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A84. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African‐Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , Cooper JrJAD , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: A randomized trial. Annals of Internal Medicine2005;143(5):317‐326. [CTG: NCT00274547] RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a> </p> <p><a href="./references#CD009285-bbs2-0020" title="CarronK . A 24 week, randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of 18 mcg of tiotropium inhalation capsules administered by handihaler® once‐daily plus prn albuterol (salbutamol) vs. placebo plusprn albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy. www.trials.boehringer‐ingelheim.com. [trial number: 205.365] SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium Handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus prn salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Thoracic Society 2011 International Conference; 2011 May 13‐18; Denver. 2011; Vol. 183:A1589. TroostersT , WeismanI , DobbelsF , GiardinoN , ValluriSR . Assessing the impact of tiotropium on lung function and physical activity in GOLD Stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. The Open Respiratory Medicine Journal2011;5:1‐9. [CTG: NCT00523991] ">Trooster 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3493</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0019" title="TonnelAB . Effect of a 9‐month treatment of SPIRIVA® on health related quality of life in patients with chronic obstructive pulmonary disease. Validation of a new HRQoL questionnaire appropriate to common daily practice. (TIPHON Study). www.trials.boehringer‐ingelheim.com. [trial number: 205.256] TonnelAB , BravoML , BrunM . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonnelAB , PerezT , GrosboisJM , BravoML , BrunM . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of COPD2008;3(2):301‐10. [CTG: NCT00274053] ">Tonnel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0001" title="BatemanED . A randomised, double‐blind, placebo‐controlled, parallel‐group study to assess long term (one‐year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.372] BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. [CTG: NCT00387088] ">Bateman 2010a</a> </p> <p><a href="./references#CD009285-bbs2-0002" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. [CTG: NCT00168831; CTG: NCT00168844] Cooper , C . A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one‐year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler. www.trials.boehringer‐ingelheim.com (accessed 05 March 2008). [trial number: 205.392] HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6:245‐51. SinghSD . A randomised, double‐blind, placebo‐controlled, parallel group efficacy and safety comparison of one‐year treatment of two doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of tiotropium inhalation solution delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.255] SmithD . A Randomised, Double‐Blind Placebo Controlled, Parallel Group Efficacy and Safety Comparison of One‐year Treatment of Two Doses (5 μg [2 actuations of 2.5 μg] and 10 μg [2 actuations of 5 μg]) of Tiotropium Inhalation Solution Delivered by the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.254] ">Bateman 2010b</a> </p> <p><a href="./references#CD009285-bbs2-0005" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology and Therapeutics2005;18(2):75‐81. CasaburiR , BriggsDDJr , DonohueJF , SerbyCW , MenjogeSS , The US Tiotropium Study Group. The spirometric efficacy of once‐daily dosing with tiotropium in stable COPD: a 13‐week multicenter trial. Chest2000;118(5):1294‐302. CasaburiR , MahlerDA , JonesPW , WannerA , San PedroG , ZuwallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5. FriedmanM , MenjogeSS , AntonSF , KestenS . Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics2004;22(11):741‐9. KestenS , FlandersJ , MenjogeSS , SerbyC . Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one‐year placebo‐controlled clinical trials [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:24. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD Conference; 2003; November 14‐15, 2003; Arlington, Virginia. 2003:Abstract no: 1189. KestenS , MenjogeSS , WitekT . The impact of COPD exacerbations (EXAC) on health related quality of life (HRQL) is attenuated by tiotropium [Abstract]. International Primary Care Respiratory Group Congress; 2002; June 7‐9; Amsterdam. 2002:23. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (spiriva™), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. San PedroG , EliasDJ , SerbyCW , WitekTJ . Tiotropium (spiriva™): one year bronchodilator efficacy established with once daily dosing in COPD patients. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A749. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SerbyCW , Schwartzstein , Jones , Ries , Killian . Tiotropium: 1‐Yr studies versus placebo/ipratropium. European Respiratory Review2002;12(82):40‐2. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [Abstract]. European Respiratory Society Annual Congress; 2002; September 14‐18; Stockholm. 2002:P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. WitekTJJr , MahlerDA . Meaningful effect size and patterns of response of the transition dyspnea index. Journal of Clinical Epidemiology2003;56(3):248‐55. ZuwallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW . Tiotropium (spiriva™) improves health status in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ZuwallackR , MorganrothJ , LanesS , KestenS . Electrocardiographic evaluations in COPD patients treated with tiotropium in one‐year clinical trials [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:A035 Poster D78. ">Casaburi 2002</a> </p> <p><a href="./references#CD009285-bbs2-0006" title="ChanC . Spiriva assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long‐term treatment in patients with COPD. A one‐year parallel group, double‐blind, randomised, placebo‐controlled study. Boehringer Ingelheim Clinical Trial Register2005. [trial number : 205.259] ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal2007;14(8):465‐72. [CTG: NCT00277264] ">Chan 2007</a> </p> <p><a href="./references#CD009285-bbs2-0009" title="DusserD . Effect of inhaled tiotropium bromide (18 mcg once daily) on the severity of airflow obstruction during long‐term treatment in patients with moderately severe COPD. Impact on severity and incidence of exacerbations. A one‐year parallel‐group, double‐blind, randomized, placebo‐controlled study. www.trials.boehringer‐ingelheim.com. [trial number: 205.214] DusserD , BravoML , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. [CTG: NCT00274014] DusserD , BravoML , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , BravoML , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513. DusserD , VielK , BravoML , LaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , LanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19‐24; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a> </p> <p><a href="./references#CD009285-bbs2-0016" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society Annual Meeting; 2006 May 19‐24 2006; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco, California, USA. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. [CTG: NCT00405236] PowrieJ , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661. WedzichaJA . A randomised, double‐blind, parallel‐group, placebo‐controlled study to evaluate the changes in inflammatory markers and in induced sputum following treatment with tiotropium inhalation capsules 18 μg once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.270] ">Powrie 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8967</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0007" title='CooperC . A randomized, double‐blind, placebo‐controlled two‐year trial to examine the changes in exercise endurance and COPD patients treated with tiotropium (Spiriva® HandiHaler®) 18 μg once daily (EXACTT trial). www.trials.boehringer‐ingelheim.com. [trial number: 205.368] CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of COPD2010;5:375‐85. [CTG: NCT00525512] CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. "Treadmill endurance during 2 years" treatment with tiotropium in patients with COPD. American Journal of Respiratory and Critical Care Medicine2011;183:A4586. '>Cooper 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009285-bbs2-0018" title="AntoniuSA . UPLIFT Study: The effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BraidoF . UPLIFT study: The results and their implications. Multidisciplinary Respiratory Medicine. 2009; Vol. 4, issue Suppl 1:6s‐12s. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A4482. CorhayJL , LouisR . The UPLIFT study. Revue Medicale de Liege2009;64(1):50‐5. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2009:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010, issue Meeting Abstracts:A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. The Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105:1523‐30. FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the uplift trial [Abstract]. 15th Congress of the Asian Pacific Society of Respirology; 2010 November 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology2011;16:825‐35. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[E4353]. HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. InoueH , AsaiY . UPLIFT (understanding potential long‐term impacts on function with tiotropium) study. Respiration and Circulation2009;57(8):813‐8. KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1 ‐ evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Thoracic Society (ATS) International Conference; 2010 May 14‐19; New Orleans. 2010. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: A pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD) [A tiotropiumterápia cardiovascularis biztonságossága krónikus obstruktív tüdőbetegségben (COPD)]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . &quot;Prince Charming&quot;? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , DeLucas RamosP . The UPLIFT study: future perspectives [Estudio UPLIFT: perspectivas futuras]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. TashkinD . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com. [trial number: 205.235] TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Society 15th Annual Congress; 2005 September 17 ‐ 21; Copenhagen. 2005; Vol. 26, issue Suppl 49:Abstract No. 4203. TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: Results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1? 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: The UPLIFT trial. Expert Review of Respiratory Medicine2010;4(3):279‐89. TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans. 2010. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008; Vol. 359, issue 15:1543‐54. [CTG: NCT00144339] TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial. Chest2009;136(4):52. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the UPLIFT trial. Chest2009;136(4):24‐25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to gender in a global respiratory trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial [Abstract]. European Respiratory Society Annual Congress; 2009 September 12‐16; Vienna. 2009:[P3808]. TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: Secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5993</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study duration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/full#CD009285-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009285-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tiotropium versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Quality of life (SGRQ total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.89 [‐3.35, ‐2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Patients with ≥ 4 units improvement in quality of life (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.38, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Patients with ≥ 4 units worsening in quality of life (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.59, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Subgroup analysis: Quality of life ICS/ no ICS (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.86 [‐4.79, ‐0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ICS users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.27 [‐5.62, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Non‐ICS users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.05 [‐5.38, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Subgroup analysis: Quality of life LABA/ no LABA (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.27 [‐3.96, ‐2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 LABA users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.8 [‐4.05, ‐1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Non‐LABA users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.48 [‐4.32, ‐2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Subgroup analysis: Quality of life (SGRQ) by disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.28 [‐4.67, ‐1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 GOLD I and II, mild and moderate, FEV1 ≥ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.66 [‐4.20, ‐1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 GOLD III and IV, severe and very severe, FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐9.22, ‐2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Quality of life (EQ‐5D total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life (CRQ total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Patients with ≥ 1 exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: patients with ≥ 1 exacerbation by study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.66, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 1 year or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Subgroup analysis: patients with ≥ 1 exacerbations ICS/ no ICS by concomitant medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p> (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.84, ‐0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 ICS users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p> (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐0.95, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Non‐ICS users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p> (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.92, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Subgroup analysis: patients with ≥ 1 exacerbation by inhaler device <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Dry Powder Inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Soft Mist Inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.67, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Subgroup analysis: patients with ≥ 1 exacerbation by disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 GOLD II, moderate, 50% ≤ FEV1 &lt; 80% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 GOLD III, severe, 30% ≤ FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 GOLD IV, very severe, FEV1 &lt; 30% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.51, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Patients with ≥ 1 exacerbation requiring hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Patients with ≥ 1 hospitalisation (all‐cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.57, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 1 year or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by inhaler device <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Dry Powder Inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Soft Mist Inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.68, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Subgroup analysis: patients with ≥ 1 exacerbation requiring hospitalisation by disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 GOLD II, moderate, 50% ≤ FEV1 &lt; 80% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.61, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 GOLD III, severe, 30% ≤ FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.90, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 GOLD IV, very severe, FEV1 &lt; 30% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.77, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Subgroup analysis: mortality by study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.49, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 1 year or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Subgroup analysis: mortality by inhaler device <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Dry Powder Inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Soft Mist Inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.04, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Subgroup analysis: mortality LABA/ no LABAby concomitant medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 LABA users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Non‐LABA users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Subgroup analysis: mortality ICS/LABA/ no ICS/LABA by concomitant medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 ICS/LABA users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Non‐ICS/LABA users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Subgroup analysis: mortality ICS/ no ICS by concomitant medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 ICS users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Non‐ICS users</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Subgroup analysis: mortality by disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 GOLD I/II, FEV1 ≥ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 GOLD III, 30% ≤ FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 GOLD IV, FEV1 &lt; 30% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.62, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Trough FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>118.92 [113.07, 124.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Patients with ≥ 1 serious adverse event (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.59, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Sensitivity analysis of SGRQ responders imputing 0% for missing participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.41, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Sensitivity analysis of SGRQ responders imputing 20% for missing participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.36, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tiotropium versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009285.pub3/references#CD009285-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009285.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009285-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009285-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009285-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD009285-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009285\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009285\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009285\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009285\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009285.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009285.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009285.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009285.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009285.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714394814"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009285.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714394818"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009285.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6d9e9bf19377',t:'MTc0MDcxNDM5NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 